MIPR NO: 92MM2525

TITLE: SUBCHRONIC TOXICITY STUDIES ON 1,3,5-TRINITROBENZENE,

1,3-DINITROBENZENE, AND TETRYL IN RATS

SUBTITLE: 14-Day Toxicity Evaluation of 1,3-Dinitrobenzene

in Fischer 344 Rats

PRINCIPAL INVESTIGATOR: Tirumuru V. Reddy, Ph.D.

CONTRACTING

ORGANIZATION: Environmental Monitoring Systems Laboratory

U.S. Environmental Protection Agency

26 W. Martin Luther King Drive Cincinnati, Ohio 45268-0001

REPORT DATE: September 1, 1994

TYPE OF REPORT: Final Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command,

Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;

distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DITIC QUALITY INSPECTED 3

19950207054

DOCUMENTATION PAGE Form Approved REPORT OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503. REPORT TYPE AND DATES COVERED AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. **FUNDING NUMBERS** TITLE AND SUBTITLE Subchronic Toxicity Studies on 1,3,5-Trinitrobenzene, 1,3-Dinitrobenzene and Tetryl in Rats SUBTITLE: 14-Day Toxicity Evaluation of 1,3-Dinitrobenzene in MIPR No. 92MM2525 Fischer 344 Rats AUTHOR(S) Tirumuru V. Reddy, F.B. Daniel, M. Robinson G.R. Olson, B. Wiechman, G. Reddy PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) PERFORMING ORGANIZATION REPORT NUMBER Environmental Monitoring Systems Laboratory U.S. Environmental Protection Agency 26 W. Martin Luther King Drive Cincinnati, Ohio 45268-0001 10. SPONSORING/MONITORING SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) AGENCY REPORT NUMBER U.S. Army Medical Research and Materiel Command, Fort Detrick, Frederick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for public release; distribution unlimited 13. ABSTRACT (Maximum 200 words) Toxic effects of 1,3-Dinitrobenzene (1,3-DNB) in male and female F344 rats were evaluated by feeding powdered certified laboratory chow diet supplemented with varied concentrations of 1,3-DNB (0, 2.5, 10, 25, 75 and 150 mg/kg diet) for fourteen days. The average daily 1,3-DNB doses consumed were 0.21, 0.87, 2.02, 6.28 and 11.82 mg/kg b.w. for females and 0.21, 0.80, 1.98, 5.77 and 10.56 for males. Food consumption was significantly decreased in high dose animals of both sexes. Final body weights were not altered but relative organ weights were significantly changed in the 150 and 75 mg dose groups involving the spleen (males and females) and testes (males). Hematology and clinical chemistry studies indicated significantly increased values in both sexes relating to reticulocytes and methemoglobin in the 150 and 75 mg/kg dose groups while the red blood cell count, hemoglobin level and % hematocrit were decreased in these same groups. In addition, the levels of bilirubin, protein and albumin were increased in high dose males, Histopathological evaluations suggested that the susceptible organs for 1,3-DNB toxicity were kidneys (hyaline droplets), spleen (erythroid cell hyperplasia), brain (malacia and microgliosis), testes (seminiferous tubular degeneration). These changes were noted mainly in the 150 and 75 mg/kg dose groups except those changes involving the brain (150 mg/kg group only). 15. NUMBER OF PAGES 14. SUBJECT TERMS 14-Day Oral Toxicity 16. PRICE CODE Fischer 344 Rats Clinical Chemistry Hematology 1,3-Dinitrobenzene

19. SECURITY CLASSIFICATION

OF ABSTRACT

unclassified

18. SECURITY CLASSIFICATION

OF THIS PAGE

unclassified

OF REPORT

17. SECURITY CLASSIFICATION

unlimited

20. LIMITATION OF ABSTRACT

QUALITY ASSURANCE STATEMENT

The portions of this toxicology project performed and reported by Pathology Associates, Inc. has been inspected and audited by the quality assurance unit as required by the Good Laboratory Practice (GLP) standards promulgated by the U.S. Environmental Protection Agency. The following table is a record of the inspections/audits performed and reported by the QAU.

Phase Inspected	Date Findings Reported to Management and Study Director
Final Report	12-30-94
Draft Report	09-22-94
	08-03-94
	07-27-94
Chemistry Analysis	06-23-94
	Final Report Draft Report Quality Control Embedding

Willa Fox, MA

Quality Assurance Unit

PAI-Cin

Date

1-5-95

Accesio	n For	
NTIS DTIC Unanno Justifica	TAB ounced	
By Distribu	ition/	
A	vailability	Codes
Dist	Avail an Spec	
A-1		

Study Number: 94-003

Compliance Statement

This study was conducted in compliance with the Good Laboratory Practice Regulations as set forth in Title 21 of the U.S. Code of Federal Regulations Part 792 issued August 17, 1989. All deviations from the protocol and/or GLPs are listed in Appendix J. There were no deviations from the aforementioned regulations which affected the quality or integrity of the study or the interpretation of the results in the report.

Times V. Rosof	12,30.94
Tirumuru V. Reddy, Ph.D.	Date
U.S. Environmental Protection Agency	
, , , , , , , , , , , , , , , , , , ,	
Greg R. Olson, D.V.M., Ph.D.	12/30/94
Cros P. Olson D.V.M. Ph.D.	72/30/94 Date
Pathology Associates, Inc.	Date
Pathology Associates, inc.	
	, ,
Ini d. Torsella	12/30/94
Joni A. Torsella, Ph.D.	Date
U.S. Environmental Protection Agency	
olo, ziviloimiona, vetesasis igais,	
	-
Barry C. Weekman	12-29-94
Barry E. Wiechman, B.S., M.S.	Date

Pathology Associates, Inc.

Study Personnel

Principal Investigator: Tirumuru V. Reddy, Ph.D.

Co-Principal Investigator: F. Bernard Daniel, Ph.D.

Biochemist: Barry E. Wiechman, B.S., M.S.

Pathologist: Greg R. Olson, D.V.M., Ph.D.

Biostatistician: Joni A. Torsella, Ph.D.

Study Biological Technician: Bradley Peterson, A.S.

Histology Laboratory Supervisor: Sheree Lovelace, A.S.

Contract Officer Representative: Gunda Reddy, Ph.D.

Study Timetable:

Study Initiation: June 7, 1994

Initiation of Dosing: June 21, 1994

Completion of Necropsy: July 6, 1994

TABLE OF CONTENTS

		Page Number
Resul Sumn	ials and Methods ts nary ences	1 2 5 9 10 11
Appendi	ces	
Α.	Food and Water Consumption Data	22
B.	Body Weights	25
C.	Organ Weights	27
D.	Hematology Data	34
E.	Clinical Chemistry Data	39
F.	Clinical Observations	44
G.	Gross and Histopathology Data	46
Н.	Chemical Analyses	114
I.	Protocol and Amendments Deviations from GLP's and Protocol	118

INTRODUCTION

Nitroaromatics, such as 1,3-dinitrobenzene (DNB), 1,3,5-trinitrobenzene (TNB), and N-methyl-N,2,4,6-tetranitroaniline (tetryl), have been detected as environmental contaminants of groundwater and soil near production sites and in some instances at military test grounds. TNB is formed during the nitration step of TNT synthesis as a result of oxidation of methyl groups. Although the complete mechanism of TNB formation during TNT photolysis is unknown, it has been suggested that it is produced by decarboxylation of 2,4,6-trinitrobenzaldehyde, a major TNT photoproduct (Burlinson, 1980). It is also found in aquatic systems and surface soils as a by-product of photolysis of TNT. DNB and TNB are not easily biodegradable, persist in the environment, eventually leach out, and contaminate groundwater near waste disposal sites. Tetryl is an explosive that has been in use, largely for military purposes, since 1906. Wastewaters and soil at the original production sites and other plants devoted to munitions assembly, contain large quantities of these compounds (Walsh and Jenkins, 1992).

Toxicity data on these compounds are limited. The oral LD50 of DNB, TNB and tetryl were 59 mg/kg, 284 mg/kg and greater than 5 g/kg, respectively, in rats for combined sexes. TNB and tetryl were not toxic at 2 g/kg when applied to rabbit skin for 24 hours. However, the dermal LD50 of DNB was 1.99 g/kg for combined sexes of rabbits. None of these compounds produced skin irritation but positive (DNB) and severe (TNB, tetryl) eye irritation potentials in rabbits were noted. The sensitization tests showed that DNB and tetryl are not skin sensitizers while TNB caused mild allergic reaction in guinea pigs (Fitzgerald et. al., 1992 a,b,c). Some of the toxicological effects of DNB are: formation of methemoglobin, testicular degeneration and reproductive failure, weight loss and anemia in hamsters, rats and mice. Neurological and hematological disorders have also been reported in dogs. DNB is toxic to humans; the estimated lethal dose range is 5-50 mg/kg. It is readily absorbed through the skin (Von Burg, 1989). Tetryl was observed to be a powerful skin sensitizer in ammunition plant Dermatitis, liver atrophy, spleen effects, headaches, weight loss and respiratory irritation were reported following tetryl exposure (U.S. EPA, 1990). Atmospheric concentration of 1.5 mg/m³ or below did not produce systemic poisoning in persons working with tetryl. DNB, TNB, and tetryl have been shown to be genotoxic in the Salmonella mutagenesis assay (McGregor et. al., 1989). TNB has also been shown to form adducts of blood proteins and tissue DNA in rats (Reddy et. al., 1991).

Objective of the Study

This study was conducted in order to evaluate the toxicity of DNB when administered in the diet for 14 days and to provide data to select doses for a 90 day subchronic study.

MATERIALS AND METHODS

Test Material Preparation

1,3-Dinitrobenzene powder (CAS #99-65-0) was prepared by Fluka Chemical Corp. (Ronkonkoma, New York). The purity (99.0%) was confirmed by the U.S. EPA, Cincinnati. Certified powdered Purina Laboratory Chow 5002 was purchased (Ralston-Purina Co., St. Louis, MO) and stored at 4°C until used. DNB diets were prepared weekly. First, .225 g of DNB was added to 25 g of powdered diet in a mortar and thoroughly ground with a pestle. Afterwards 1475 g of the diet was added and mixed for 60 minutes in a mechanical mixer (Kitchen Aid, St. Joseph, MI)) for uniform distribution of DNB in the diet. This was verified by determining the DNB concentration in the diet, taken from each of the 1 kg mixtures, by quantitative analysis done by HPLC. The premixed diet (150 mg/kg) was further diluted with fresh powdered diet to obtain the desired DNB concentration in the lower dose groups. The diet feeders were refilled twice a week and changed weekly.

Analyses of the DNB-feed mixtures were carried out on acetone extracts of the mixtures, utilizing a Waters 600E chromatography system (Waters, Milford, MA), equipped with a 490E programmable multiwavelength detector, operating at 245 nm. The entire chromatography system was interfaced with a Berthold HPLC computer program, Version 1.65 (Berthold, Nashua, NH). The DNB was eluted from a Zorbax C-8 column (9.4 mm x 25 cm) (MAC-DOD Analytical, Chadds Ford, PA) with a watermethanol gradient, at a flow rate of 3 ml/min. The gradient had an initial condition of 20% methanol which was increased in a linear fashion from 20% to 50% in 15 minutes and then to 65% in 25 minutes, and finally to 100% in 10 minutes. The column was washed for an additional 5 minutes and brought back to 20% methanol by reverse gradient and equilibrated for an additional 10 minutes at initial conditions before the next sample was injected. Working standards were prepared in Burdick and Jackson HPLC grade high purity methanol (Baxter, Obetz, OH). Analytical data of these mixtures is present in Appendix H.

Animals and Maintenance

Male and female Fischer 344 rats, confirmed free of viral antibodies, bacteria and parasites, were obtained from Charles River Laboratories, Kingston, New York. The animals, 6 weeks old and weighing approximately 120-125 g when delivered, were held for 2 weeks in quarantine prior to initiation of treatment. The animals were housed in a temperature (20-22°C) and humidity (40-60%) controlled room on a 12:12 hour light:dark cycle. For the study, they were housed individually in polycarbonate cages and water was administered ad libitum. Animal identification was done using electronic implants (Bio Medic, Maywood, NJ) with the rats assigned to control and treatment groups according to a computer-generated set of random numbers. The weight variation of the animals of each sex used did not exceed \pm 2 s.d. of the mean weight at the time of delivery. The cages were identified with a color-coded identification card indicating the animal and treatment group. All aspects of the study were conducted in compliance with the guidelines of the American Association for Accreditation of Laboratory Animal Care.

All rats were observed twice daily for physiological and behavioral responses as well as for mortality or morbidity. Food and water consumption were recorded twice weekly. Body weights were taken prior to the start of the study, once weekly during the study and at the final sacrifice.

Experiment Design

Group	No. of Ar	nimalsAnimal Nos.	Sex	Diet Concentration (mg DNB/kg diet)
1	5	1-5	F	150
2	5	6-10	F	75
3	5	11-15	F	25
4	5	16-20	F	10
5	5	21-25	F	2.5
6	5	26-30	F	0
7	5	31-35	M	150
8	5	36-40	M	75 .
9	5	41-45	M	25
10	5	46-50	M	10
11	5	51-55	M	2.5
12	5	56-60	M	0

Hematology and Clinical Chemistry

Hematology parameters were assessed using a Serono-Baker Hematology Analyzer, Model 9000, coupled to a computer running Labcat[®] software (Innovation Programming, Inc., Princeton, NJ). Total red and white blood cell counts, platelet count, reticulocyte count, differential leukocyte count, hemoglobin and packed cell volume were measured and computed. Methemoglobin samples were analyzed on a IL 482 Co-Oximeter. Heinz bodies were determined using the crystal violet procedure (Lee et. al., 1993) with microscopic examination for positive cells (>5 Heinz bodies).

Clinical chemistry was performed using a COBAS Fara II centrifugal analyzer (Roche, Nutley, NJ) with a non-selective electrode (ISE) module. This system was also interfaced with a personal computer and the Labcat software system. Clinical chemistry analytes included sodium, potassium, total protein, albumin, calcium, phosphorus, total bilirubin, blood urea nitrogen, creatinine, alanine aminotransferase, cholesterol, triglycerides, aspartate aminotransferase, glucose and alkaline phosphatase.

Statistical Evaluation

Males and females were considered separately in all statistical analyses. A one-factor (dose) analysis of variance (ANOVA) was used to analyze normally distributed measures: body weights, organ weights, organ weight ratios, food and water consumption, hematology and clinical chemistry. When a treatment effect was noted (p \leq 0.05, F-test) the difference between the control and the treatment groups was probed using a multiple comparison procedure (Dunnett's t-test).

Necropsy and Histopathology

Prior to necropsy, the animals were anesthetized with pentobarbital (60 mg/kg b.w., i. p.) and blood samples were collected via cardiac puncture after the body weight was recorded. Following euthanasia via exsanguination, all external surfaces, orifices, external surface of the brain, cervical tissues, all organs, and the thoracic, abdominal and pelvic cavities were examined for gross lesions.

During necropsy the following tissues were weighed: brain, liver, spleen, kidneys, adrenals, lungs, thymus, testes w/epididymides, ovaries, and heart.

The following tissues were harvested from each animal and preserved in 10% neutral buffered formalin:

skin⁻ mandibular and mesenteric lymph nodes mammary glands thigh muscle sciatic nerve sternum femur with marrow thymus trachea lungs with bronchi heart and aorta thyroid parathyroids esophagus stomach duodenum jejunum tongue

salivary gland

harderian gland

ileum

colon cecum rectum liver pancreas spleen kidneys adrenals urinary bladder seminal vesicles prostate testes, including epididymides ovaries uterus nasal cavity with turbinates brain pituitary

preputial or clitoral glands Zymbal's gland thoracic spinal cord eyes

Subsequently, these tissues were trimmed, processed and embedded in paraffin. Blocks were sectioned at 5μ and slides were prepared and stained with hematoxylin and eosin. All tissues were examined in the high dose and control groups of both sexes. The brain and spleen of both sexes and the testes and kidneys of males were identified as target organs and examined in the appropriate groups.

The inflammatory and degenerative lesions were graded according to severity using a scale of one to four (minimal, mild, moderate or marked). Data were tabulated according to individual animal and summarized by group. In addition, the gross observations and microscopic diagnoses were correlated for each animal. Labcat histopathology software was used for data management.

Specimen, Raw data, and Final Report Storage

All tissue specimens, blocks and slides, raw data and final report will be placed in the U.S. EPA storage facility.

RESULTS

Food and Water Consumption

Food and water consumption data are listed in Table 1, while individual data are presented in Appendix A. Food consumption was significantly ($p \le 0.05$) decreased in both sexes receiving 150 mg DNB diet while water consumption was not significantly altered in any group.

Using the food consumption data, the average daily DNB dose levels received by group (see Experimental Design) are presented in Table 2. The average daily DNB doses consumed (mg/kg b.w.) were 12, 6, 2, 0.9 and 0.2 for females and 11, 6, 2, 0.8 and 0.2 for males.

Body Weights, Organ Weights and Weight Ratios

The mean group values for body weights are listed in Table 3 while mean group organ weights (heart, brain, spleen, adrenals, thymus, ovaries/testes, kidneys, lungs and liver) are given in Tables 4 (females) and 5 (males). Mean group values for organ to body weight ratios are present in Tables 6 (females) and 7 (males). Individual body weights are found in Appendix B with individual organ weights present in Appendix C.

No significant decreases from control terminal body weights were noted in any of the treated groups.

Organ weights as a percent of the total body weight were significantly (p \leq 0.05) different from controls for the following organs:

Kidneys - The 25 mg DNB dose group (males) had an increased value.

Liver - The 150 mg DNB dose group of both sexes had increased values.

Spleen - The 150 and 75 mg DNB dose groups of both sexes had increased values along with the 25 mg DNB female group.

Testes - The 150 and 75 mg DNB dose groups had decreased values.

Hematology

Hematology analyses performed were total white blood cell count (WBC), platelet count, red blood count (RBC), methemoglobin, hemoglobin (HGB), hematocrit (HCT), reticulocytes, Heinz bodies and differential leukocyte count. Group data are summarized in Tables 8 (females) and 9 (males). Individual data are listed in Appendix D.

1. WBC and Differential:

There were no significant differences in total white cell count or differentials amongst the groups in either sex except for the 75 mg DNB dose group (females) which had a decreased WBC count.

2. RBC:

A significant decrease (p \leq 0.05) in red blood cell count was present in both sexes receiving 150 and 75 mg DNB diet and in the female 25 mg DNB dose group.

3. Hemoglobin:

A significant decrease (p \leq 0.05) was noted in hemoglobin levels in both sexes in the 150, 75 and 25 mg DNB dose groups.

4. Hematocrit:

A significant decrease (p \leq 0.05) was present in both sexes in the 150 and 75 mg DNB dose groups and in the female 25 mg DNB dose group.

5. Platelets:

There were no significant changes in total platelets in any treatment group except for a slight increase in the female 75 mg DNB dose group.

6. Reticulocytes:

A significant increase (p \leq 0.05) was noted only in both sexes in the 150 and 75 mg DNB dose groups and the female 25 mg DNB dose group.

7. Methemoglobin:

A significant increase (p \leq 0.05) was present in both sexes receiving 150, 75 and 25 mg DNB diet and the 10 mg DNB male group.

8. Heinz Bodies:

Heinz bodies were not evident in any treatment group.

Clinical Chemistry

The mean group values for each analyte are compiled in Tables 10 (females) and 11 (males). Individual data are present in Appendix E.

1. Total Protein:

The mean values for females ranged from 5.6 to 5.9 g/dl while in males the range was 6.2 to 6.8. Significant increases (p \leq 0.05) occurred in only the male 150 mg DNB dose group.

2. Albumin:

The mean values for females ranged from 4.2 to 4.3 g/dl while in males the range was 4.5 to 5.0. Significant increases (p \leq 0.05) were present in only the male 150 mg DNB dose group.

3. Calcium:

The mean values for females ranged from 10.3 to 10.5 mg/dl while in males the range was 10.5 to 11.3. Significant increases ($p \le 0.05$) were evident in only the male 150 mg DNB dose group.

4. Total Bilirubin:

The mean values for females ranged from 0.10 to 0.18 mg/dl while in males the range was 0.10 to 0.16 Males receiving 150 and 75 mg DNB diet had significant increased ($p \le 0.05$) values. No changes were evident in females.

5. Blood Urea Nitrogen (BUN):

The mean values for females ranged from 21.2 to 25.0 mg/dl while in males the range was 19.6 to 23.4. There were significant increases (p \leq 0.05) occurring in only the 75 and 25 mg DNB male dose groups.

6. Creatinine:

The mean values for females ranged from 0.50 to 0.60 mg/dl while in males the range was 0.58 to 0.66. There were no significant differences amongst the groups except for a slight increase in the female 75 mg DNB dose group.

7. Aspartate Aminotransferase (AST):

The mean values for females ranged from 110 to 152 IU/L while in males the range was 113 to 183. There were no significant differences amongst the groups except for a slight increase in the female 75 mg DNB dose group.

8. Alanine Aminotransferase (ALT):

The mean values for females ranged from 38 to 53 IU/L while in males the range was 46 to 81. There were no significant differences amongst the groups.

9. Alkaline Phosphatase (ALK Phos):

The mean values for females ranged from 150 to 189 IU/L while in males the range was 186 to 193. There were no significant changes amongst the groups.

10. Sodium:

The mean values for females ranged from 142 to 143 mmol/L while in males the range was 142 to 143. There were no significant differences amongst the groups.

11. Potassium:

The mean values for females ranged from 4.4 to 5.2 mmol/L while in males the range was 4.5 to 5.1. There were no significant differences amongst the groups.

12. Glucose:

The mean values for females ranged from 95 to 116 mg/dl while in males the range was 145 to 167. There were no significant differences amongst the groups.

13. Phosphorus:

The mean values for females ranged from 10.6 to 12.9 mg/dl while in males the range was 10.5 to 11.9. There were no significant changes amongst the groups.

14. Cholesterol:

The mean values for females ranged from 84 to 100 mg/dl while in males the range was 51 to 67. There were no significant differences amongst the groups except for a slight increase in the male 150 mg DNB dose group.

15. Triglycerides:

The mean values for females ranged from 28 to 38 mg/dl while in males the range was 56 to 79. There were no significant differences amongst the groups.

Clinical Observations

Clinical observations are listed in Appendix F. There were no clinical observations that were meaningful.

Mortality

There were no early deaths in any of the groups.

Gross Pathology

Gross changes noted at the terminal sacrifice were confined to the 150 and 75 mg/kg DNB dose groups. There changes included a dose related increase in spleen size or a decrease in testicular size.

Histopathology (Appendix G)

All tissues were histopathologically examined in control and high dose animals of both sexes while the brain, spleen, testes and kidneys (males only) were examined in all the remaining dose groups. Significant changes were evident in the high dose (150 mg/kg DNB) group of both sexes involving bone marrow, spleen and brain. Brain lesions (cerebellar peduncles) featured prominent areas of cellular vacuolization, microgliosis and necrosis. The spleen and bone marrow were characterized by a minimal to moderate erythroid cell hyperplasia and pigment deposition (hemosiderin). Only the spleen was examined in all the animals since this same compensatory change can be noted in multiple organs. Regenerative anemia, as noted by the hematology results was the probable initiating factor for this response. Similar splenic changes were noted in the 75 and 25 mg/kg groups but with a decreased severity.

Additional microscopic changes were apparent in the male 150 and 75 mg/kg DNB groups entailing the kidneys and testes. The kidneys exhibited an increase in hyaline droplet deposition along with an increased incidence an/or severity of tubular degeneration and regeneration. The testes were characterized by moderate to severe seminiferous tubular degeneration. The affected tubules were lined by fewer spermatogenic cells and contained a reduced number of mature spermatides. Cell debris and some multinucleated cells were also present in the tubules as well as in the ducts of the epididymis. The diameter of the affected tubules was decreased with the interstitium being more condensed and prominent.

The remaining diagnoses were considered spontaneous since their incidence levels were significantly low.

SUMMARY

The administration to Fischer 344 rats of 1,3-Dinitrobenzene at various doses in the diet for fourteen days resulted in the following significant findings:

- 1. A significant decrease in average daily food consumption in both sexes receiving 150 mg DNB diet.
- 2. Relative kidney weights were significantly increased in male rats receiving 25 mg DNB diet while relative liver weights were increased in both sexes in the 150 mg dose group.
- 3. Relative spleen weights were increased in both sexes in the 150 and 75 mg DNB diet groups and the female 25 mg dose group while testicular weights were decreased in the 150 and 75 mg DNB dose groups.
- 4. A significant decrease in red blood cell count, hemoglobin and hematocrit levels were apparent in both sexes receiving 150 and 75 mg DNB diet while reticulocyte levels were increased in these same groups. Methemoglobin levels were increased in both sexes receiving 150, 75 and 25 mg DNB diet and the male 10 mg dose group.
- Microscopic examination revealed significant changes in the testes (seminiferous tubular degeneration), spleen (erythroid cell hyperplasia), kidneys (hyaline droplet deposition) and brain (vacuolization, microgliosis and necrosis). Brain changes were evident in both sexes in the 150 mg DNB

group with kidney and testicular changes present in the 150 and 75 mg male groups. The 150, 75 and 25 mg DNB groups of both sexes exhibited splenic changes of varying severity.

REFERENCES

Burlinson, N.E. (1980) Fate of TNT in an Aquatic Environment: Photodecomposition vs. Biotransformation. Final report. Silver Spring, Maryland: Naval Weapons Center, NSWC/TR-79-445.

Fitzgerald, G.B., Austin, A., Desai, L.S. and Reddy, G. (1992a). Acute Toxicological Evaluation of N-Methyl-N, 2,4,6-Tetranitroaniline. J. Amer. Coll., Toxicol. Acute Toxicity Data: Part B. 1, 167-168.

Fitzgerald, G.B., DiGiulio, N., Desai, L.S. and Reddy, G. (1992b). Acute Toxicological Evaluation of 1,3-Dinitrobenzene. J. Amer. Coll., Toxicol. Acute Toxicity Data: Part B. 1, 168-169.

Lee, R.G., Bithell, T.C., and Foerster, J. (1993). Wintrobe's Clinical Hematology, p.1048.

Fitzgerald, G. B., DiGiulio, N., Desai, L. S. and Reddy, G. (1992c). Acute Toxicological Evaluation of 1,3,5-Trinitrobenzene. J. Amer. Coll., Toxicol. Acute Toxicity Data: Part B. 1, 169-170.

McGregor, D.B., Riach, C.G., Hastwell, R.M. and Dacre, J.C. (1980). Genotoxic Activity in Microorganisms of Tetryl, 1,3-Dinitrobenzene and 1,3,5-Trinitrobenzene. Environ. Mut. 2, 531-541.

Reddy, T.V., Wan, L., Lin, E.L.C., Daniel, F.B. and Reddy, G. (1991). Formation and Persistence of 1,3,5-Trinitrobenzene Adducts with Blood Proteins and Tissue DNA. Toxicologist, 11, 131.

U.S. EPA. (1990). Health and Environmental Effects Document for Trinitrophenylmethylnitramine. Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH. ECAO-CIN-GO91.

Von Burg, R. (1989). Toxicology Update: Dinitrobenzene. J. Appl. Toxicol. 9, 199-202.

Walsh, M.E. and Jenkins, T.F. (1992). Identification of TNT Transformation Products in Soil. U.S. Army Corps of Engineers, Cold Regions Research and Engineering Laboratory, Special Report 92-16.

Table 1: Food and Water Consumption

Dose	Food	Water
(mg DNB/kg diet)	(g/kg b.w./day)	(g/kg b.w./day)
	Fema	ales
0	86.84±0.97	120.01±5.29
150	78.15±3.74 *	112.33±6.56
75	84.24±1.89	116.19±3.15
25	83.20±1.17	114.64±2.72
10	85.83±1.82	121.21±4.16
2.5	86.15±0.25	111.28±2.26
	Mal	es
0	78.32±1.17	106.54±4.10
150	69.81±0.74 *	98.61±2.99
75	77.34±2.07	101.19±3.62
25	81.28±0.96	107.12±3.11
10	79.36±2.18	104.90±6.04
2.5	80.69±2.00	101.01±2.08

^{*}Significantly different from the control group (p≤0.05) by Dunnett's test.

Table 2: Calculated Daily DNB Consumption

		Dose	Calculated
		Groups	Dose
Group	Sex	(mg DNB/kg diet)	(mg DNB/kg b.w.)
1	F	150	11.82±0.57
2	F	75	6.28±0.14
3	F	25	2.02±0.03
4	F	10	0.87±0.02
5	F	2.5	0.22±0.00
6	F	0	
7	М	150	10.56±0.11
8	М	75	5.77±0.15
9	М	25	1.98±0.02
10	М	10	0.80±0.02
11	М	2.5	0.21±0.01
12	М	0	

Table 3: Body Weights (grams)

Dose Groups	Weeks		
(mg DNB/kg diet)	1	2	
	Fema	ales	
0	132.93±3.24	140.92±3.87	
150	129.42±0.91	134.97±1.57	
75	135.07±2.54	144.67±2.54	
25	134.74±2.76	143.68±3.30	
10	133.63±1.50	143.21±1.78	
2.5	134.21±2.14	143.25±2.61	
	Mal	es	
0	199.21±4.92	222.40±4.77	
150	198.01±2.58	212.03±2.74	
75	196.13±2.92	216.53±2.88	
25	198.07±5.27	221.45±5.92	
10	195.35±8.36	217.27±9.60	
2.5	195.29±5.13	216.84±5.79	

Table 4: Organ Weights (grams)/Females

	Dose Groups (mg DNB/kg diet)					<u> </u>
	0	150	75	25	10	2.5
Kidneys	1.10±0.01	1.07±0.04	1.14±0.04	1.12±0.04	1.15±0.01	1.12±0.02
Lungs	0.82±0.04	0.81±0.03	0.88±0.05	0.84±0.04	0.89±0.07	0.77±0.04
Liver	4.17±0.13	4.63±0.33	4.61±0.18	4.50±0.19	4.26±0.11	4.39±0.08
Heart	0.57±0.02	0.54±0.04	0.58±0.04	0.56±0.02	0.61±0.03	0.57±0.02
Brain	1.68±0.04	1.69±0.02	1.68±0.02	2.26±0.64	1.70±0.03	1.69±0.02
Spleen	0.36±0.01	0.68±0.05 *	0.74±0.03 *	0.45±0.03	0.37±0.01	0.38±0.01
Adrenals	0.08±0.01	0.06±0.00	0.14±0.07	0.07±0.00	0.07±0.00	0.08±0.00
Thymus	0.29±0.03	0.28±0.02	0.36±0.03	0.31±0.01	0.31±0.02	0.30±0.04
Gonad	0.13±0.01	0.11±0.01	0.15±0.01	0.12±0.02	0.15±0.01	0.13±0.01

^{*} Significantly different from the control group (p \leq 0.05) by Dunnett's test.

Table 5: Organ Weights (grams)/Males

	Dose Groups (mg DNB/kg diet)					
	0	150	75	25	10	2.5
Kidneys	1.69±0.06	1.64±0.06	1.69±0.05	1.82±0.06	1.70±0.08	1.68±0.04
Lungs	1.09±0.08	1.10±0.05	0.96±0.04	1.04±0.06	1.11±0.05	1.08±0.04
Liver	7.70±0.20	7.91±0.36	7.58±0.20	7.77±0.30	7.39±0.45	7.13±0.22
Heart	0.78±0.01	0.72±0.03	0.75±0.02	0.78±0.03	0.78±0.04	0.75±0.02
Brain	1.82±0.02	1.79±0.01	1.81±0.03	1.78±0.03	1.78±0.05	1.83±0.03
Spleen	0.51±0.02	1.05±0.02 *	0.98±0.03 *	0.58±0.02	0.51±0.02	0.47±0.01
Adrenals	0.06±0.01	0.06±0.00	0.05±0.00	0.05±0.01	0.06±0.00	0.06±0.01
Thymus	0.32±0.02	0.30±0.02	0.33±0.04	0.40±0.03	0.35±0.02	0.36±0.02
Gonad	3.91±0.22	1.98±0.21 *	1.78±0.05 *	3.77±0.18	4.05±0.32	4.00±0.25

^{*} Significantly different from the control group (p \leq 0.05) by Dunnett's test.

Table 6: Organ-to-Body Weight Ratios/Females

	Dose Groups (mg DNB/kg diet)					
	0	150	75	25	10	2.5
Body Weight(g)	139.68±3.38	132.88±3.87	141.68±3.37	139.68±3.29	136.22±5.16	141.37±2.12
Kidneys (%)	0.79±0.01	0.80±0.01	0.80±0.01	0.80±0.02	0.85±0.03	0.79±0.01
Lungs (%)	0.59±0.03	0.61±0.01	0.62±0.03	0.61±0.03	0.66±0.06	0.54±0.03
Liver (%)	2.98±0.05	3.47±0.15 *	3.25±0.05	3.21±0.07	3.14±0.09	3.10±0.04
Heart (%)	0.41±0.02	0.41±0.03	0.41±0.02	0.40±0.01	0.45±0.03	0.40±0.01
Brain (%)	1.20±0.03	1.27±0.03	1.19±0.02	1.62±0.45	1.26±0.05	1.19±0.02
Spleen (%)	0.26±0.00	0.51±0.03 *	0.52±0.01 *	0.32±0.01 *	0.28±0.01	0.27±0.01
Adrenals (%)	0.06±0.00	0.05±0.00	0.10±0.05	0.05±0.00	0.05±0.00	0.05±0.00
Thymus (%)	0.21±0.02	0.21±0.01	0.25±0.02	0.22±0.01	0.23±0.01	0.21±0.02
Gonad (%)	0.10±0.01	0.08±0.01	0.10±0.01	0.09±0.01	0.11±0.01	0.09±0.01

^{*} Significantly different from the control group (p \leq 0.05) by Dunnett's test.

Table 7: Organ-to-Body Weight Ratios/Males

			Dose Groups (m	g DNB/kg diet)		
	. 0	150	75	25	10	2.5
Body Weight(g)	222.59±4.34	202.31±4.03	213.50±3.47	221.41±5.84	217.04±9.97	215.89±5.56
Kidneys (%)	0.76±0.02	0.81±0.02	0.79±0.01	0.82±0.02 *	0.78±0.01	0.78±0.02
Lungs (%)	0.49±0.04	0.54±0.02	0.45±0.02	0.47±0.03	0.51±0.01	0.50±0.02
Liver (%)	3.46±0.03	3.90±0.11 *	3.55±0.07	3.50±0.05	3.40±0.06	3.30±0.03
Heart (%)	0.35±0.01	0.35±0.01	0.35±0.01	0.35±0.01	0.36±0.01	0.35±0.01
Brain (%)	0.82±0.02	0.89±0.02	0.85±0.02	0.80±0.01	0.83±0.04	0.85±0.02
Spleen (%)	0.23±0.01	0.52±0.01 *	0.46±0.01 *	0.26±0.01	0.23±0.01	0.22±0.00
Adrenals (%)	0.03±0.00	0.03±0.00	0.02±0.00	0.02±0.00	0.03±0.00	0.03±0.00
Thymus (%)	0.14±0.01	0.15±0.01	0.15±0.02	0.18±0.01	0.16±0.01	0.17±0.01
Gonad (%)	1.76±0.11	0.97±0.09 *	0.83±0.03 *	1.71±0.11	1.87±0.14	1.86±0.14

^{*} Significantly different from the control group (p \leq 0.05) by Dunnett's test.

Table 8: Hematology Values/Females

		Do	se Groups	(mg DNB/	kg diet)	
	0	150	75	25	10	2.5
RBC	7.96	6.01 *	6.01 *	7.18*	7.70	7.81
(x10 ⁶ /μl)	±0.21	±0.34	±0.31	±0.37	±0.16	±0.16
Hemoglobin	15.50	12.74*	12.56 *	13.64*	14.82	15.16
(g/dl)	±0.40	±0.57	±0.65	±0.65	±0.27	±0.24
Hematocrit	41.92	39.08*	38.90 *	38.84*	41.16	41.88
(%)	±0.85	±2.18	±1.39	±1.22	±1.22	±1.80
WBC	4.36	3.12	2.94 *	3.92	3.24	3.42
(x10 ³ /μl)	±1.13	±0.37	±0.67	±0.99	±0.75	±0.69
Platelets	747.00	773.40	877.40 *	786.25	811.67	776.00
(x10 ³ /μί)	±30.21	±83.53	±79.36	±35.45	±29.74	±59.29
Segmented Leukocytes (%)	17.12 ±4.43	12.22 ±1.58	15.40 ±5.74	17.14 ±5.13	18.30 ±3.51	17.15 ±3.66
Lymphocytes	79.40	84.54	80.26	79.70	77.78	78.82
(%)	±4.52	±1.58	±5.51	±5.97	±4.00	±4.63
Heinz Bodies	0.0	0.0	0.0	0.0	0.0	0.0
(%)	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00
MCV	52.70	65.04*	64.72 *	54.14	53.44	53.64
(cumicr)	±0.57	±0.53	±1.97	±1.87	±1.56	±1.71
MCH	19.50	21.20*	20.88 *	18.96*	19.28	19.44
(picogm)	±0.29	±0.34	±0.27	±0.30	±0.15	±0.24
MCHC	37.02	32.58*	32.28 *	35.08*	36.08	36.28
(g/dl)	±0.59	±0.44	±1.24	±1.09	±0.97	±1.45
Reticulocytes (%)	1.62	9.24*	12.54 *	4.28*	2.38	2.05
	±0.11	±1.12	±0.65	±0.41	±0.17	±0.22
MetHb	0.62	7.24*	4.70 *	2.90 *	1.40	0.82
(%)	±0.25	±1.20	±0.27	±0.31	±0.19	±0.31

Mean ± Standard Deviation
* Significantly different from the control group (P≤ 0.05) by the Dunnett's test.

Table 9: Hematology Values/Males

		Do	se Groups	(mg DNB/	kg diet)	
	0	150	75	25	10	2.5
RBC	8.45	6.55 *	7.05 *	8.19	8.30	8.40
(x10 ⁶ /μl)	±0.18	±0.15	±0.29	±0.09	±0.17	±0.19
Hemoglobin	15.58	12.90*	13.18 *	14.68*	15.30	15.62
(g/dl)	±0.38	±0.42	±0.58	±0.23	±0.32	±0.32
Hematocrit	45.88	42.78*	41.94 *	44.12	45.10	45.58
(%)	±1.08	±1.49	±1.43	±1.04	±0.32	±1.62
WBC	4.52	4.42	4.98	4.66	4.10	4.02
(x10 ³ /μl)	±0.75	±1.39	±0.93	±0.79	±1.39	±0.70
Platelets	849.40	947.00	984.00	945.80	883.00	899.00
(x10 ³ /μL)	±28.06	±60.51	±66.98	±59.84	±52.05	±14.53
Segmented Leukocytes (%)	20.40 ±4.03	15.78 ±4.36	15.00 ±2.97	17.60 ±2.55	16.14 ±3.10	18.70 ±2.11
Lymphocytes	76.60	80.62	82.40	80.02	81.32	78.48
(%)	±4.64	±4.63	±3.44	±2.53	±3.38	±2.01
Heinz Bodies	0.0	0.0	0.0	0.0	0.0	0.0
(%)	±0.00	±0.00	±0.00	±0.00	±0.00	±0.00
MCV	54.30	65.30*	59.58 *	53.86	54.38	54.28
(cumicr)	±0.64	±2.21	±1.46	±1.09	±1.20	±1.25
MCH	18.44	19.70*	18.72	17.92*	18.48	18.58
(picogm)	±0.21	±0.24	±0.24	±0.11	±0.26	±0.18
MCHC	33.94	30.20*	31.42 *	33.28	34.00	34.28
(g/dl)	±0.74	±1.06	±0.87	±0.72	±0.67	±1.08
Reticulocytes (%)	2.62	10.90*	9.12 *	4.12	2.66	2.30
	±0.40	±2.00	±1.54	±0.29	±0.23	±0.27
MetHb	0.74	8.78*	6.28 *	3.34*	1.78*	0.62
(%)	±0.34	±0.74	±0.74	±0.59	±0.47	±0.29

Mean ± Standard Deviation
* Significantly different from the control group (P≤ 0.05) by the Dunnett's test.

Table 10: Clinical Chemistry Values/Females

		Do	Dose Groups (mg DNB/kg diet)	B/kg diet)		
	0	150	75	25	10	2.5
Glucose (mg/dl)	113.60 ± 23.03	110.60 ± 30.91	94.60 ± 19.14	115.80 ± 25.61	103.20 ± 30.63	105.00 ± 18.75
BUN (mg/dl)	21.20 ± 1.79	24.00 ± 2.55	25.00 ± 2.35	23.00 ± 2.55	24.40 ± 4.16	23.80 ± 2.49
Creatinine (mg/dl)	0.50 ± 0.00	0.54 ± 0.05	0.60 ± 0.07 *	0.52 ± 0.04	0.54 ± 0.05	0.50 ± 0.00
ALK Phos. (U/L)	170.40 ± 14.15	188.80 ± 58.64	150.40 ± 25.55	160.00 ± 21.51	154.20 ± 13.55	164.80 ± 22.62
AST (U/L)	116.80 ± 5.50	114.60 ± 16.10	152.00 ± 35.23*	109.60 ± 4.83	133.60 ± 12.54	126.40 ± 18.61
ALT (U/L)	46.80 ± 6.83	53.20 ± 15.14	41.80 ± 7.66	40.20 ± 5.07	38.00 ± 7.18	47.20 ± 8.87
Potassium (mmol/L)	4.58 ± 0.31	4.88 ± 0.63	5.24 ± 0.56	4.52 ± 0.48	4.42 ± 0.28	4.62 ± 0.22
Albumin (g/dl)	4.26 ± 0.15	4.44 ± 0.21	4.48 ± 0.26	4.36 ± 0.19	4.32 ± 0.16	4.26 ± 0.13
Calcium (mg/dl)	10.40 ± 0.23	10.48 ± 0.13	10.46 ± 0.36	10.36 ± 0.15	10.30 ± 0.12	10.42 ± 0.19
Sodium (mmol/dl)	142.00 ± 0.71	143.20 ± 1.92	141.40 ± 1.14	142.20 ± 0.84	143.00 ± 1.00	142.60 ± 0.55
Total Bilirubin (mg/dl)	0.12 ± 0.04	0.14 ± 0.05	0.18 ± 0.04	0.12 ± 0.04	0.12 ± 0.04	0.10 ± 0.00
Total Protein (g/dl)	5.64 ± 0.28	5.70 ± 0.20	5.90 ± 0.31	5.88 ± 0.29	5.84 ± 0.11	5.78 ± 0.22
Cholesterol (mg/dl)	89.20 ± 3.70	83.60 ± 5.55	89.60 ± 8.65	90.40 ± 9.61	94.20 ± 6.72	100.20 ± 3.11
Phosphorus (mg/dl)	10.60 ± 0.87	10.66 ± 1.27	12.94 ± 1.47	10.60 ± 1.56	10.74 ± 2.19	11.08 ± 1.55
Triglyceride (mg/dl)	38.00 ± 5.48	34.60 ± 15.95	31.40 ± 9.63	29.00 ± 1.87	28.20 ± 6.06	36.00 ± 9.11
Mosp + Standard Davistion	iotion noite					

Mean ± Standard Deviation

*Significantly different from the control group (p≤0.05) by the Dunnett's test.

Table 11: Clinical Chemistry Values/Males

		Dos	Dose Groups (mg DNB/kg diet)	B/kg diet)		
	0	150	75	25	10	2.5
Glucose (mg/dl)	150.20 ± 19.25	144.80 ± 39.73	166.80 ± 27.67	156.60 ± 18.98	150.00 ± 27.18	152.20 ± 25.02
BUN (mg/dl)	20.00 ± 1.22	20.80 ± 1.30	23.40 ± 0.89*	22.60 ± 2.51*	19.60 ± 1.52	20.00 ± 1.00
Creatinine (mg/dl)	0.62 ± 0.04	0.60 ± 0.00	0.64 ± 0.05	0.66 ± 0.05	0.58 ± 0.04	0.58 ± 0.04
ALK Phos. (U/L)	193.40 ± 10.01	186.40 ± 32.07	189.40 ± 7.40	190.80 ± 4.60	190.40 ± 13.92	193.40 ± 13.74
AST (U/L)	141.00 ± 23.31	113.00 ± 15.30	133.00 ± 34.60	183.40 ± 84.99	123.60 ± 9.29	144.40 ± 27.69
ALT (U/L)	57.40 ± 10.14	49.60 ± 8.71	61.00 ± 22.27	81.20 ± 55.58	45.80 ± 9.73	51.00 ± 8.75
Potassium (mmol/L)	4.66 ± 0.30	5.14 ± 0.79	5.08 ± 0.48	4.84 ± 0.23	4.54 ± 0.26	4.90 ± 0.50
Albumin (g/dl)	4.54 ± 0.05	4.98 ± 0.08*	4.74 ± 0.19	4.62 ± 0.16	4.52 ± 0.16	4.52 ± 0.11
Calcium (mg/dl)	10.62 ± 0.23	11.26 ± 0.30*	10.90 ± 0.47	10.52 ± 0.23	10.78 ± 0.29	10.68 ± 0.40
Sodium (mmol/dl)	142.80 ± 1.10	142.20 ± 0.45	141.60 ± 1.14	142.60 ± 1.34	143.20 ± 1.30	143.40 ± 1.52
Total Bilirubin (mg/dl)	0.10 ± 0.00	0.16 ± 0.05 *	$0.16 \pm 0.05^*$	0.10 ± 0.00	0.10 ± 0.00	0.10 ± 0.00
Total Protein (g/dl)	6.20 ± 0.19	$6.76 \pm 0.11^*$	6.36 ± 0.21	6.28 ± 0.18	6.22 ± 0.23	6.22 ± 0.11
Cholesterol (mg/dl)	52.40 ± 3.36	$67.00 \pm 4.85^*$	57.40 ± 6.11	51.20 ± 4.27	57.60 ± 1.95	52.20 ± 4.97
Phosphorus (mg/dl)	10.52 ± 0.61	11.88 ± 1.01	11.24 ± 1.27	11.30 ± 1.25	11.00 ± 0.73	11.24 \pm 0.94
Triglyceride (mg/dl)	73.80 ± 22.63	56.40 ± 26.06	57.20 ± 21.18	65.60 ± 25.08	79.40 ± 16.68	68.40 ± 9.18
Moon + Ctondard Dovietion	intion					

Mean ± Standard Deviation

*Significantly different from the control group (p≤0.05) by the Dunnett's test.

APPENDIX A

FOOD AND WATER CONSUMPTION

Weekly Food and Water Consumption

Dose	Food	(g/wk)	Water	(g/wk)
(mg DNB/kg diet)	Week	Week	Week	Week
(g = ··=···g · · · /	1	2	1	2
		Fem	nales	
0	82.94±2.82	84.60±1.15	117.92±5.08	113.10±5.09
150	76.28±1.58	68.96±5.30	106.00±4.60	103.48±6.62
75	85.06±4.35	81.68±1.60	116.40±4.79	112.26±5.44
25	81.16±1.65	82.54±1.94	113.36±3.02	110.64±2.29
10	82.24±1.35	85.30±2.25	119.30±4.25	115.88±5.40
2.5	82.00±1.95	87.08±1.22	110.38±3.05	105.88±2.65
		Ма	les	
0	100.20±3.47	133.22±4.20	137.28±5.16	175.78±7.94
150	93.38±1.52	106.86±3.42	130.44±2.28	149.76±5.85
75	97.43±2.80	127.74±3.08	125.45±5.66	166.10±7.44
25	103.42±3.95	137.20±3.37	137.40±4.85	175.72±6.27
10	99.80±4.95	131.20±7.15	134.54±10.43	166.84±12.81
2.5	102.32±2.85	131.62±3.87	125.84±3.76	162.38±4.49

Individual Food and Water Consumption

			Ferr	nales			Males			
		Food	(g/wk)	Water	(g/wk)		Food	(g/wk)	Water	(g/wk)
Dose	Animal					Animal				
(mg DNB/kg diet)	Number	Week 1	Week 2	Week 1	Week 2	Number	Week 1	Week 2	Week 1	Week 2
150	1	77.7	63.4	100.4	88.5	31	98.0	107.1	136.2	155.9
	2	74.3	52.7	105.2	104.0	32	91.0	115.0	124.5	151.3
	3	72.2	69.6	107.0	99.1	33	91.9	111.0	128.9	135.4
	4	81.5	84.1	122.4	128.0	34	95.9	94.6	127.3	138.7
	5	75.7	75.0	95.0	97.8	35	90.1	106.6	135.3	167.5
75	6	102.3	87.0	123.6	122.1	36	*	130.5	*	186.9
	7	81.2	83.1	125.8	124.9	37	96.5	126.0	128.8	171.4
	8	78.8	80.0	122.1	115.3	38	97.4	133.3	118.2	150.7
	9	80.4	77.5	109.6	99.9	39	91.1	116.5	114.9	147.5
	10	82.6	80.8	100.9	99.1	40	104.7	132.4	139.9	174.0
25	11	78.9	85.7	107.8	109.8	41	105.6	138.1	128.5	165.5
	12	87.6	85.2	120.3	113.4	42	106.2	146.0	148.9	174.0
	13	80.2	85.5	119.4	112.0	43	115.7	142.6	148.9	198.8
	14	78.7	75.8	114.1	115.7	44	95.3	127.9	126.6	163.7
	15	80.4	80.5	105.2	102.3	45	94.3	131.4	134.1	176.6
10	16	85.5	88.1	136.3	133.1	46	103.4	138.7	147.7	187.5
	17	79.7	77.6	115.1	115.4	47	105.7	139.7	148.0	177.6
	18	80.8	83.7	115.6	113.5	48	109.8	141.5	139.4	173.7
	19	85.5	90.8	114.5	99.3	49	81.3	103.2	93.3	116.4
	20	79.7	86.3	115.0	118.1	50	98.8	132.9	144.3	179.0
2.5	21	86.4	91.8	115.6	106.8	51	107.6	140.9	136.1	172.5
	22	85.2	86.5	111.5	111.7	52	109.3	139.8	128.0	163.2
	23	82.9	86.3	116.9	111.2	53	101.6	126.3	130.5	171.6
	24	79.9	84.7	99.9	98.3	54	93.5	120.8	115.8	149.8
	25	75.6	86.1	108.0	101.4	55	99.6	130.3	118.8	154.8
0	26	91.0	87.5	117.3	110.2	56	113.0	147.3	153.4	202.2
	27	87.7	84.3	126.5	123.5	57	98.9	136.8	131.6	171.3
	28	76.7	84.6	110.8	109.8	58	99.0	122.3	122.5	152.5
	29	82.0	86.0	131.5	124.8	59	98.3	129.4	137.0	177.1
	30	77.3	80.6	103.5	97.2	60	91.8	130.3	141.9	175.8

^{*} Excess Spillage

APPENDIX B BODY WEIGHTS

Weekly Body Weights (grams)

Dose	Animal	We	eks	Animal			
(mg DNB/kg diet)	Number	1	2	Number	1	2	
		Fem	ales		Ма	les	
150	1	131.47	137.20	31	204.50	218.43	
	2	128.23	129.40	32	203.37	218.83	
•	3	130.17	137.17	33	195.23	207.83	
	4	126.47	133.53	34	196.03	208.97	
	5	130.77	137.53	35	190.90	206.07	
75	6	142.60	152.00	36	203.47	223.40	
73	7	137.40	147.13	37	196.57	215.50	
	8	136.47	146.33	38	201.33	222.83	
	9	130.43	139.40	39	191.13	209.07	
	10	128.47	138.47	40	188.13	211.87	
	10	120.17	.00.17				
25	11	140.87	150.57	41	202.17	224.70	
	12	140.27	150.10	42	208.33	234.37	
	13	135.80	145.73	43	207.73	232.33	
	14	129.57	137.80	44	191.20	212.27	
	15	127.20	134.20	45	180.93	203.57	
10	16	136.87	149.20	46	209.63	231.00	
10	17	136.60	144.60	47	207.77	231.70	
	18	132.43	140.83	48	209.30	234.73	
	19	133.53	142.60	49	172.10	187.40	
	20	128.70	138.80	50	177.93	201.53	
					044.07	000.00	
2.5	21	140.73	151.93	51	211.07	236.03	
	22	136.60	145.37	52	198.73	220.77	
	23	134.50	143.10	53	193.23	215.67	
	24	130.33	138.17	54	194.27	210.57	
	25	128.87	137.70	55	179.17	201.17	
0	26	141.63	151.57	56	212.17	236.07	
	27	138.80	147.60	57	208.07	230.53	
	28	131.13	139.77	58	198.97	220.20	
	29	129.30	134.93	59	190.07	214.27	
	30	123.77	130.73	60	186.80	210.93	

APPENDIX C ORGAN WEIGHTS

INDIVIDUAL ORGAN WEIGHTS (GRAMS)

1 1 129.65 1.066 0.775 4.280 0.82 1 2 121.06 0.939 0.718 3.614 0.7	6 0.593 2.985
1 2 121.06 0.939 0.718 3.614 0.7 1 3 131.02 1.076 0.812 4.584 0.83 1 4 140.20 1.076 0.883 5.213 0.70 1 5 142.47 1.176 0.875 5.445 0.83 2 6 153.18 1.297 0.951 5.281 0.83 2 7 143.25 1.114 0.938 4.558 0.77 2 8 141.77 1.134 0.973 4.638 0.80 2 9 133.42 1.056 0.809 4.195 0.73 2 10 136.80 1.092 0.730 4.372 0.79 3 11 145.05 1.163 0.970 4.675 0.80 3 12 148.50 1.193 0.773 4.961 0.80 3 14 133.09 1.001 0.774 4.032 0.73 3 15 131.55 1.056 0.861 4.080	67 0.630 3.718 85 0.614 3.822 67 0.621 3.448 7 0.655 3.182 80 0.655 3.144 80 0.534 3.196 80 0.669 3.223 80 0.521 3.341 80 0.582 3.030 80 0.582 3.101 81 0.483 3.127 82 0.641 3.121 83 0.564 3.083 84 0.564 3.083 85 0.611 3.014 88 0.528 2.977 89 0.534 3.121 80 0.534 3.125 80 0.577 3.127 80 0.572 2.984 92 0.714 2.968

INDIVIDUAL ORGAN WEIGHTS (GRAMS)

7 31 208.86 1.705 1.020 7.998 0.816 0.488 3.829 7 32 214.67 1.822 1.285 9.284 0.849 0.599 4.325 7 33 198.05 1.646 1.043 7.484 0.831 0.527 3.779 7 34 196.35 1.491 1.072 7.350 0.759 0.546 3.743 7 35 193.62 1.538 1.058 7.444 0.794 0.546 3.845 8 36 216.69 1.721 0.885 7.547 0.794 0.408 3.483 8 37 214.07 1.663 1.076 7.630 0.777 0.503 3.564 8 38 224.02 1.834 0.963 7.939 0.819 0.430 3.544 8 39 203.43 1.540 0.859 6.847 0.757 0.422 3.366 8 40 209.27 1.681 1.013 7.933 0.803 0.484 3.791 9 41 223.08 1.744 1.054 7.736 0.782 0.472 3.468 9 42 235.71 1.966 1.020 8.498 0.834 0.433 3.605 9 43 232.08 1.935 1.028 8.368 0.834 0.443 3.606 9 44 209.79 1.674 0.883 7.049 0.798 0.421 3.3606 9 44 209.79 1.674 0.883 7.049 0.798 0.421 3.3606 9 45 206.38 1.800 1.234 7.177 0.872 0.598 3.478 10 46 230.74 1.842 1.144 8.024 0.798 0.496 3.478 10 47 231.46 1.784 1.211 7.788 0.771 0.523 3.3655 10 48 235.52 1.829 1.177 8.406 0.777 0.500 3.569 10 49 184.71 1.390 0.948 5.911 0.753 0.513 3.200 10 50 202.76 1.657 1.066 6.837 0.817 0.523 3.365 11 52 220.39 1.711 0.926 7.230 0.776 0.420 3.281 11 53 212.49 1.660 1.115 7.058 0.781 0.525 3.322 11 54 208.39 1.542 1.103 6.636 0.740 0.529 3.184 11 55 203.15 1.688 1.138 6.811 0.831 0.560 3.353 12 56 236.17 1.857 1.241 8.229 0.786 0.525 3.484 12 57 229.56 1.786 0.947 8.132 0.778 0.413 3.542 12 58 217.14 1.522 0.913 7.360 0.701 0.420 3.390	GP-	ANI BER	BODY WEIGHT	KIDNEY WEIGHT	LUNGS WEIGHT	LIVER WEIGHT	% KIDNEY	f LUNGS	% LIVER
	7777888889999901001111111111111111111111	33333333444444444555555555555555555555	214.67 198.05 196.35 193.62 216.69 214.07 224.02 203.43 209.27 235.71 232.08 209.79 206.38 230.74 231.46 235.52 184.71 202.76 235.05 212.49 208.39 203.15 229.56 217.14 214.84	1.822 1.646 1.491 1.538 1.723 1.663 1.540 1.544 1.935 1.681 1.746 1.842 1.849 1.662 1.7662 1.7662 1.542 1.542 1.542 1.542 1.542 1.542 1.542	1.285 1.043 1.072 1.058 0.885 1.076 0.963 0.859 1.020 1.028 0.883 1.244 1.144 1.217 0.948 0.925 1.103 1.138 1.247 0.947 0.913 1.298	9.284 7.354 7.444 7.547 7.639 7.934 7.937 7.94 8.368 7.174 7.938 8.368 7.174 7.828 7.938 7.938 7.938 7.938 7.938 7.358 7.358	0.849 0.831 0.759 0.794 0.777 0.819 0.757 0.834 0.783 0.798 0.777 0.753 0.775 0.775 0.776 0.776 0.7781 0.7781 0.7781 0.788	0.599 0.527 0.546 0.408 0.430 0.432 0.424 0.423 0.423 0.423 0.423 0.596 0.5513 0.5526 0.5529 0.5529 0.5529 0.5529 0.5529 0.604	4.325 3.779 3.743 3.845 3.483 3.564 3.564 3.366 3.4605 3.4605 3.478 3.4605 3.478 3.3600 3.478 3.373 3.383 3.383 3.383 3.383 3.384 3.

INDIVIDUAL ORGAN WEIGHTS (GRAMS)

GP-Z		BODY WEIGHT	HEART WEIGHT	BRAIN WEIGHT	SPLEEN WEIGHT	% HEART	% BRAIN	% SPLEEN
111112222233333444455555666666	123456789012345678901234567890	129.65 121.06 131.02 140.20 142.47 153.18 143.27 133.42 136.80 145.05 140.22 133.55 146.61 124.36 137.45 142.98 137.61 141.79 143.79 141.79 143.79 141.79 143.79 145.55 148.64 145.55 138.82 135.49 129.91	0.460 0.460 0.662 0.584 0.585 0.685 0.6552 0.6539 0.5562 0.5538 0.5578 0.648 0.5537 0.648 0.5537 0.5537 0.5537 0.5537 0.6584	1.645 1.645 1.660 1.777 1.677 1.627 1.623 1.623 1.623 1.623 1.627 1.639 1.627 1.639 1.639 1.639 1.648 1.714 1.6739 1.648 1.739 1.648 1.739 1.648 1.655 1.655 1.655 1.655 1.655 1.657	0.706 0.517 0.736 0.634 0.814 0.812 0.727 0.789 0.652 0.7536 0.452 0.379 0.409 0.358 0.358 0.360 0.349 0.349 0.349 0.349 0.349 0.352 0.340	0.386 0.380 0.505 0.357 0.410 0.447 0.390 0.462 0.384 0.363 0.401 0.363 0.402 0.394 0.394 0.396 0.472 0.376 0.472 0.376 0.432 0.388 0.370 0.432 0.388 0.370 0.447	1.300 1.359 1.267 1.263 1.177 1.206 1.216 1.2216 1.2216 1.223 1.237 1.233 1.237 1.244 1.2176 1.156 1.265 1.2	0.545 0.427 0.562 0.4571 0.530 0.557 0.489 0.557 0.307 0.322 0.307 0.322 0.285 0.286 0.254 0.257 0.287 0.257 0.2557 0.2557 0.262 0.262

INDIVIDUAL ORGAN WEIGHTS (GRAMS)

GP-ANI	BODY	HEART	BRAIN	SPLEEN	%	%	%
NUMBER	WEIGHT	WEIGHT	WEIGHT	WEIGHT	HEART	BRAIN	SPLEEN
7 31 7 32 7 33 7 35 8 37 8 38 8 40 9 41 9 44 9 44 10 48 10 49 10 11 51 11 55 11 55 12 11 55 12 12 12 12 12 12 12 12 12 12 12 12 12 1	208.86 214.67 198.05 196.35 193.62 216.69 214.02 203.43 209.28 235.71 232.09 235.74 235.74 235.55 1202.76 235.39 212.49 203.49 203.43 209.78 215.55 216.69 217.65 220.39 218.69 218.69 218.69 219.78 219.7	0.709 0.810 0.655 0.676 0.740 0.804 0.721 0.754 0.755 0.728 0.728 0.728 0.749 0.842 0.749 0.842 0.749 0.749 0.736 0.736 0.738 0.736 0.738 0.738 0.738	1.807 1.793 1.740 1.817 1.908 1.778 1.813 1.7784 1.847 1.847 1.847 1.855 1.855 1.855 1.850 1.860	1.008 1.103 1.003 1.004 1.047 0.978 0.975 0.873 1.038 0.559 0.559 0.5523 0.5523 0.5523 0.5523 0.429 0.514 0.455 0.470 0.465 0.5453 0.5491	0.339 0.377 0.331 0.344 0.382 0.371 0.337 0.337 0.348 0.366 0.366 0.339 0.342 0.356 0.356 0.356 0.351 0.358 0.351 0.351 0.351 0.353 0.363 0.363 0.363	0.865 0.835 0.879 0.925 0.928 0.8847 0.874 0.874 0.874 0.877 0.821 0.821 0.803 0.748 0.748 0.788	0.483 0.514 0.506 0.549 0.445 0.445 0.429 0.254 0.254 0.254 0.267 0.267 0.223 0.223 0.223 0.2218 0.2218 0.2229 0.225 0.225 0.225 0.225 0.2218

INDIVIDUAL ORGAN WEIGHTS (GRAMS)

GP-ANI	BODY	ADRENAL	THYMUS	OVARIES	%	%	%
NUMBER	WEIGHT	WEIGHT	WEIGHT	WEIGHT	ADRENAL	THYMUS	OVARIES
1 1 1 2 1 3 1 4 1 5 2 6 2 7 2 8 9 10 3 11 3 12 3 14 15 16 4 17 4 18 4 19 4 20 5 21 5 22 5 26 6 27 6 29 6 30	129.65 121.06 131.20 142.47 153.18 143.25 141.77 133.42 1345.55 1440.22 133.55 146.36 137.61 1247.61 1	0.058 0.059 0.072 0.067 0.066 0.069 0.058 0.065 0.071 0.070 0.074 0.057 0.088 0.079 0.068 0.075 0.081 0.075 0.081 0.071 0.082 0.068 0.071	0.262 0.222 0.259 0.356 0.319 0.419 0.404 0.413 0.250 0.305 0.3310 0.327 0.336 0.376 0.375 0.275 0.272 0.247 0.307 0.301 0.247 0.301 0.301	0.110 0.149 0.084 0.107 0.141 0.109 0.181 0.152 0.146 0.174 0.123 0.136 0.158 0.158 0.159 0.152 0.154 0.152 0.154 0.152 0.154 0.152 0.154 0.152	0.045 0.045 0.045 0.046 0.046 0.045 0.045 0.045 0.045 0.045 0.055	0.202 0.183 0.198 0.254 0.224 0.274 0.282 0.291 0.225 0.225 0.225 0.227 0.227 0.227 0.227 0.227 0.298 0.297 0.297 0.212 0.297 0.212 0.213 0.212 0.223 0.223 0.223 0.219	0.085 0.083 0.114 0.060 0.075 0.092 0.128 0.114 0.107 0.120 0.083 0.097 0.062 0.116 0.088 0.116 0.081 0.104 0.096 0.111 0.096 0.1120 0.0981 0.0985 0.0981 0.120 0.120

INDIVIDUAL ORGAN WEIGHTS (GRAMS)

GP-	ANI BER	BODY WEIGHT	ADRENAL WEIGHT	THYMUS WEIGHT	TESTES WEIGHT	% ADRENAL	% THYMUS	% TESTES
7777788888999990100111111111111111111111	1234567890123456789 1234567890123456789	208.86 214.67 198.35 196.35 193.62 216.69 214.07 224.02 203.43 209.27 223.78 235.71 235.79 236.37 235.71 235.76 235.39 212.49 208.39 20	0.062 0.071 0.055 0.066 0.065 0.052 0.053 0.048 0.067 0.068 0.063 0.065 0.065 0.065 0.065 0.065 0.065 0.065 0.065 0.065	0.247 0.318 0.282 0.349 0.326 0.433 0.289 0.288 0.246 0.398 0.341 0.491 0.340 0.379 0.400 0.341 0.363 0.292 0.370 0.416 0.333 0.345 0.345 0.345 0.345 0.345 0.345	1.754 2.816 1.795 1.778 1.886 1.691 1.8891 1.622 1.8993 3.820 3.370 4.816 3.8691 4.053 3.8693 3.8793 3.8653 3.728 3.542 4.053 3.542 4.053 3.453 4.533 4.533 4.533 4.463	0.030 0.033 0.028 0.034 0.036 0.030 0.024 0.024 0.018 0.023 0.017 0.027 0.029 0.023 0.023 0.030 0.025 0.028 0.028 0.024 0.028 0.024 0.029 0.029	0.118 0.148 0.142 0.178 0.168 0.200 0.135 0.129 0.121 0.190 0.157 0.162 0.162 0.184 0.173 0.147 0.158 0.158 0.158 0.159 0.157 0.145 0.145 0.144 0.132 0.147	0.840 1.312 0.890 0.918 0.918 0.836 0.755 0.797 0.897 1.646 1.666 2.154 1.654 1.655 1.655 2.038 1.655 2.1690 1.647 2.1695 1.647 2.1695 1.695 1.695 2.1695 1.695 2.1695 1.695 2.16
12	60	215.22	0.071	0.376	4.262	0.033	0.175	1.980

APPENDIX D
HEMATOLOGY DATA

Hematology Data/Females 14 Days

DOSE			WBC	RBC			
GROUPS	ANIMALS	METHB	COUNT	COUNT	HGB	HCT	MCV
(mg DNB/kg)			thsn/	mill/			
diet	#	%	cu mm	cu mm	g/dl	%	cumicr
150	1	8.4	3.1	5.95	12.7	38.5	64.6
	2	7.0	3.2	6.57	13.7	42.6	64.9
	3	8.5	2.8	5.70	12.3	37.4	65.6
	4	5.7	2.8	5.79	12.3	37.3	64.5
	5	6.6	3.7	6.04	12.7	39.6	65.6
75	6	4.7	2.3	5.54	11.5	37.3	67.3
	7	4.6	3.3	6.22	13.1	38.5	61.8
	8	5.0	3.9	6.12	12.9	39.4	64.4
	9	4.9	2.8	6.31	12.9	41.0	64.9
	10	4.3	2.4	5.88	12.4	38.3	65.2
25	11	3.2	3.0	6.88	13.1	38.0	55.3
	12	2.7	3.7	6.97	13.0	37.7	54.1
	13	3.2	3.0	7.05	13.6	39.9	56.5
	14	2.5	5.1	7.80	14.6	40.4	51.7
	15	2.9	4.8	7.19	13.9	38.2	53.1
10	16	1.2	3.2	7.58	14.8	42.1	55.6
	17	1.7	2.9	7.81	15.1	40.3	51.6
	18	1.3	2.5	7.49	14.4	40.0	53.4
	19	1.4	4.5	7.74	14.8	40.6	52.4
	20	1.4	3.1	7.89	15.0	42.8	54.2
					4 0		50.0
2.5	21	0.8	2.7	7.94	15.3	44.4	56.0
	22	0.6	2.9	7.92	15.5	41.4	52.2
	23	0.9	3.8	7.63	15.0	39.5	51.8
	24	1.3	4.4	7.92	15.1	42.6	53.8
	25	0.5	3.3	7.63	14.9	41.5	54.4
_	0.5	4.0	0.0	7.04	15.0	41.5	53.0
0	26	1.0	3.8	7.84	15.0	41.6	53.0
	27	0.4	4.4	7.86	15.6	40.9	53.0 52.8
	28	0.7	3.6	7.74	15.2		52.6 51.7
	29	0.4	6.3	8.26	16.0	42.7	51.7
	30	0.6	3.7	8.10	15.7	42.9	53.0

Hematology Data/Females 14 Days

DOSE					NEUTRO-	LYMPHO-		HEINZ
GROUPS	ANIMALS	MCH	MCHC	PLAT	PHILS	CYTES	RETIC	BODIES
(mg DNB/kg)				thsn/				
diet	#	picogm	g/dl	cu mm	%	%	%	%
150	1	21.3	32.9	889	10.7	84.6	8.6	0.0
	2	20.8	32.1	779	10.3	86.9	7.6	0.0
	3	21.7	33.0	813	13.6	83.8	10.0	0.0
	4	21.2	32.8	696	13.2	84.8	9.7	0.0
	5	21.0	32.1	690	13.3	82.6	10.3	0.0
75	6	20.7	30.7	817	8.9	86.1	13.0	0.0
, 0	7	21.0	34.0	977	23.2	72.7	11.9	0.0
	8	21.1	32.7	946	11.6	84.4	12.8	0.0
	9	20.5	31.6	800	19.0	76.8	11.8	0.0
	10	21.1	32.4	847	14.3	81.3	13.2	0.0
25	11	19.0	34.4	811	19.6	77.6	4.9	0.0
25	12	18.6	34.5	805	16.7	81.0	4.0	0.0
	13	19.2	34.0	734	23.0	71.9	4.0	0.0
	14	18.7	36.1	*	17.3	79.6	4.0	0.0
	15	19.3	36.4	795	9.1	88.4	4.5	0.0
10	16	19.5	35.1	816	21.8	75.4	2.6	0.0
	17	19.3	37.4	780	16.2	80.1	2.2	0.0
	18	19.3	36.1	839	20.7	73.5	2.3	0.0
	19	19.2	36.6	*	14.5	82.1	2.4	0.0
	20	19.1	35.2	827	23.2	71.1	2.3	0.0
2.5	21	19.3	34.5	843	18.0	77.3	2.2	0.0
2.0	22	19.6	37.5	715	17.4	78.7	1.9	0.0
	23	19.7	38.0	776	12.6	84.7	1.7	0.0
	24	19.1	35.5	719	14.2	82.1	2.1	0.0
	25	19.5	35.9	*	17.5	79.0	2.1	0.0
0	26	10.2	26.2	*	20.1	76.1	1.5	0.0
0	26 27	19.2	36.2		11.5	84.9	1.7	0.0
	27	19.9	37.6	759 767		73.7	1.7	0.0
	28	19.7	37.3	767 760	22.7 14.5	82.1	1.7	0.0
	29	19.3	37.4 36.6	760 702	14.5	80.2	1.5	0.0
	30	19.4			10.0 sufficient	00.2	1.5	0.0

Hematology Data/Males 14 Days

DOSE			WBC	RBC			
GROUPS	ANIMALS	METHB	COUNT	COUNT	HGB	HCT	MCV
(mg DNB/kg)			thsn/	mill/			
diet	#	%	cu mm	cu mm	g/dl	%	cumicr
150	31	8.4	6.7	6.78	13.6	44.6	65.7
	32	7.9	3.9	6.38	12.7	42.6	66.7
	33	8.5	4.7	6.60	12.9	40.5	61.4
	34	9.6	3.2	6.52	12.8	43.3	66.3
	35	9.5	3.6	6.46	12.5	42.9	66.4
75	36	6.9	4.2	6.90	13.0	41.0	59.5
	37	6.3	5.0	7.36	13.6	44.0	59.8
	38	7.1	4.1	6.63	12.3	40.9	61.7
	39	5.4	5.2	7.23	13.8	42.9	59.3
	40	5.7	6.4	7.11	13.2	40.9	57.6
25	41	4.1	5.2	8.17	14.5	43.7	53.5
	42	3.4	3.8	8.09	14.4	44.0	54.4
	43	3.6	5.4	8.30	14.9	43.8	52.9
	44	2.5	3.8	8.26	14.9	45.9	55.5
	45	3.1	5.1	8.15	14.7	43.2	53.0
10	46	1.6	2.9	8.32	15.0	44.9	54.0
, 0	47	2.1	3.2	8.25	15.2	44.7	54.2
	48	2.3	4.3	8.36	15.4	45.5	54.4
	49	1.1	6.4	8.52	15.8	45.1	53.0
	50	1.8	3.7	8.05	15.1	45.3	56.3
2.5	51	0.3	3.7	8.11	15.2	43.2	53.3
2.0	52	0.9	4.9	8.60	16.0	46.6	54.2
	53	0.3	4.5	8.55	15.7	46.5	54.4
	54	0.8	3.9	8.39	15.8	44.6	53.2
	55	0.8	3.1	8.34	15.4	47.0	56.3
0	56	0.3	5.4	8.36	15.5	44.8	53.6
-	57	0.7	3.5	8.34	15.1	46.1	55.3
	58	0.9	5.1	8.74	16.1	47.3	54.1
	59	1.2	4.4	8.50	15.8	46.4	54.5
	60	0.6	4.2	8.29	15.4	44.8	54.0

Hematology Data/Males 14 Days

DOSE					NEUTRO-	LYMPHO-		HEINZ
GROUPS	ANIMALS	MCH	MCHC	PLAT	PHILS	CYTES	RETIC	BODIES
(mg DNB/kg)				thsn/				
diet	#	picogm	g/dl	cu mm	%	%	%	%
150	31	20.0	30.5	968	11.9	84.5	12.0	0.0
•	32	19.9	29.8	962	14.1	82.9	10.4	0.0
	33	19.6	31.9	840	15.7	80.2	7.8	0.0
	34	19.6	29.6	980	23.2	72.8	13.1	0.0
	35	19.4	29.2	985	14.0	82.7	11.2	0.0
75	36	18.8	31.6	945	13.9	84.1	7.0	0.0
	37	18.5	30.9	*	19.6	76.9	9.9	0.0
	38	18.6	30.2	941	15.6	81.9	8.0	0.0
	39	19.1	32.1	967	11.5	86.1	10.5	0.0
	40	18.6	32.3	1083	14.4	83.0	10.2	0.0
25	41	17.8	33.2	970	17.3	80.2	4.5	0.0
	42	17.8	32.8	918	16.9	81.4	4.1	0.0
	43	18.0	34.0	1027	18.6	79.0	4.3	0.0
	44	18.0	32.4	866	21.1	76.4	3.8	0.0
	45	18.0	34.0	948	14.1	83.1	3.9	0.0
10	46	18.1	33.5	914	17.3	79.8	2.3	0.0
10	40 47	18.4	34.0	878	18.6	78.8	2.8	0.0
	48	18.5	34.0	899	19.1	78.1	2.7	0.0
	48 49	18.6	35.1	796	12.3	85.4	2.6	0.0
	50	18.8	33.4	928	13.4	84.5	2.9	0.0
2.5	51	18.7	35.1	913	19.5	78.1	2.5	0.0
2.5	52	18.6	34.4	*	17.5	79.0	2.6	0.0
	52 53	18.4	33.8	*	21.6	75.7	2.2	0.0
	53 54	18.8	35.4	900	16.0	81.3	1.9	0.0
	5 4 55	18.4	32.7	884	18.9	78.3	2.3	0.0
	55	10.7	02.7			, 5.5		-
0	56	18.5	34.6	861	16.6	80.9	2.4	0.0
	57	18.1	32.7	818	24.4	71.3	2.3	0.0
	58	18.4	33.9	828	16.3	81.0	2.6	0.0
	59	18.6	34.1	851	20.1	77.6	2.5	0.0
	60	18.6	34.4	889	24.6	72.2	3.3	0.0
			* = Qua	ntity not	sufficient			

APPENDIX E CLINICAL CHEMISTRY DATA

Clinical Chemistries/Females 14 Days

DOSE							
GROUPS	ANIMALS	GLUCOSE	BUN	CREAT	SODIUM	POTASSIUM	CHOL
(mg DNB/kg)				7.11			ma/dl
diet	#	mg/dl	mg/dl	mg/dl	mmol/l	mmol/l	mg/dl
150	1	111	21	0.5	141	5.4	86
	2	70	23	0.6	146	4.0	90
	3	140	24	0.6	142	5.0	86
	4	91	24	0.5	144	4.5	76
	5	141	28	0.5	143	5.5	80
	•	447	20	0.6	141	4.8	79
75	6	117	29	0.6	143	5.3	99
	7	96	23	0.5			97
	8	97	24	0.6	141	6.0	
	9	64	24	0.7	140	5.5	83
	10	99	25	0.6	142	4.6	90
0.5	1.1	106	25	0.5	142	4.8	81
25	11		21	0.5	143	4.0	88
	12	120		0.6	142	5.0	92
	13	77	23		143	4.0	106
	14	141	26	0.5		4.8	85
	15	135	20	0.5	141	4.0	65
10	16	97	24	0.6	144	4.5	96
10	17	96	20	0.5	143	4.2	98
	18	73	21	0.5	142	4.1	85
	19	155	30	0.5	144	4.8	90
	20	95	27	0.6	142	4.5	102
	20	33	2,	0.0	•		
2.5	21	100	22	0.5	142	4.7	102
	22	125	27	0.5	143	4.9	104
	23	119	22	0.5	142	4.3	101
	24	77	22	0.5	143	4.6	97
	25	104	26	0.5	143	4.6	97
0	26	114	21	0.5	143	4.3	92
Ū	27	107	23	0.5	142	4.5	88
	28	82	20	0.5	142	5.0	94
	29	146	23	0.5	141	4.8	87
	30	119	19	0.5	142	4.3	85
	30		. •				

Clinical Chemistries/Females 14 Days

DOSE GROUPS	ANIMALS	AST	ALT	PHOS	AP	Са	TOTAL BILIRUBIN	TOTAL PROTEIN	ALB	TRIG
(mg DNB/kg)	AMMALO	7101	/ \L.	11.00			J.2	17101211	,,,,,	
diet	#	U/L	U/L	mg/dl	U/L	mg/dl	mg/dl	g/dl	g/dl	mg/dl
150	1	121	40	10.6	139	10.6	0.1	5.8	4.3	31
	2	128	45	11.4	162	10.4	0.1	6.0	4.8	29
	3	101	43	12.1	147	10.5	0.2	5.6	4.3	18
	4	129	63	8.7	278	10.3	0.2	5.6	4.4	61
	5	94	75	10.5	218	10.6	0.1	5.5	4.4	34
75	6	171	45	12.0	190	10.3	0.2	5.5	4.1	22
	7	116	41	10.8	155	10.8	0.2	6.2	4.8	46
	8	174	40	13.9	131	10.9	0.2	6.2	4.6	36
	9	187	52	14.1	125	10.1	0.2	5.9	4.5	27
	10	112	31	13.9	151	10.2	0.1	5.7	4.4	26
			00	44 7	454	400	0.1	5 0	4 5	00
25	11	104	38	11.7	151	10.3	0.1	5.9	4.5	29
	12	105	37	10.7	180	10.2	0.1	5.9	4.3	26
	13	112	35	12.4	133	10.6	0.2	6.0	4.3	31
	14	115	44	8.5	184	10.4	0.1	6.2	4.6	29
	15	112	47	9.7	152	10.3	0.1	5.4	4.1	30
10	16	126	39	14.2	161	10.4	0.1	5.7	4.2	18
	17	134	32	8.4	146	10.1	0.1	5.9	4.4	34
	18	148	35	10.5	136	10.3	0.1	5.8	4.1	31
	19	117	50	9.5	157	10.4	0.1	6.0	4.5	29
	20	143	34	11.1	171	10.3	0.2	5.8	4.4	29
2.5	21	125	35	12.1	158	10.2	0.1	5.7	4.2	24
	22	129	58	10.3	138	10.7	0.1	6.1	4.4	39
	23	98	51	9.0	195	10.3	0.1	5.6	4.2	49
	24	130	42	11.0	153	10.4	0.1	5.9	4.4	35
	25	150	50	13.0	180	10.5	0.1	5.6	4.1	33
0	26	113	40	10.5	155	10.6	0.1	5.9	4.4	36
	27	119	57	11.1	170	10.3	0.1	5.3	4.1	38
	28	125	41	11.5	187	10.7	0.1	5.9	4.4	44
	29	116	48	9.2	158	10.2	0.2	5.4	4.1	42
	30	111	48	10.7	182	10.2	0.1	5.7	4.3	30

Clinical Chemistries/Males 14 Days

	DOSE						507400004	01101
	GROUPS	ANIMALS	GLUCOSE	BUN	CREAT	SODIUM	POTASSIUM	CHOL
	(mg DNB/kg) diet	#	mg/dl	mg/dl	mg/dl	mmol/l	mmol/l	mg/dl
•	150	31	207	22	0.6	142	6.3	72
	100	32	131	21	0.6	142	4.1	68
		33	113	22	0.6	142	4.9	71
		34	113	19	0.6	142	5.3	61
		35	160	20	0.6	143	5.1	63
		00						
	75	36	158	23	0.7	142	5.0	55
	, 0	37	122	24	0.6	143	5.0	62
		38	181	22	0.6	141	5.9	48
		39	186	24	0.7	142	4.8	59
		40	187	24	0.6	140	4.7	63
	25	41	153	23	0.7	144	4.6	53
	20	42	154	26	0.7	142	4.7	51
		43	186	23	0.7	141	4.8	55
		44	133	22	0.6	144	4.9	53
		45	157	19	0.6	142	5.2	44
	10	46	122	18	0.6	144	4.6	55
	10	47	119	20	0.5	144	4.1	57
		48	164	18	0.6	144	4.8	59
		49	173	21	0.6	143	4.6	57
		50	172	21	0.6	141	4.6	60
	2.5	51	160	21	0.5	141	4.1	58
		52	177	19	0.6	144	4.8	49
		53	156	19	0.6	144	5.4	57
		54	158	21	0.6	143	5.2	50
		55	110	20	0.6	145	5.0	47
	0	56	159	20	0.6	143	4.4	48
		57	160	19	0.6	144	5.0	52
		58	161	22	0.7	143	4.8	51
		59	155	20	0.6	141	4.8	57
		60	116	19	0.6	143	4.3	54

Clinical Chemistries/Males 14 Days

DOSE	ANUNAALC	AST	ALT	PHOS	AP	Ca	TOTAL BILIRUBIN	TOTAL PROTEIN	ALB	TRIG
GROUPS (mg DNB/kg)	ANIMALS	ASI	ALI	F1103	Ar	Ca	BILINOBIN	THOTEM	ALD	TINIG
diet	#	U/L	U/L	mg/dl	U/L	mg/di	mg/dl	g/dl	g/dl	mg/di
150	31	102	61	12.3	162	11.6	0.2	6.8	4.9	44
	32	108	51	11.0	242	11.3	0.1	6.9	5.0	103
	33	135	52	11.0	170	10.8	0.2	6.8	5.0	45
	34	122	37	13.4	174	11.4	0.2	6.6	5.1	46
	35	98	47	11.7	184	11.2	0.1	6.7	4.9	44
						40.7	0.4	0.0	4.0	0.4
75	36	130	59	10.9	187	10.7	0.1	6.3	4.8	34
	37	121	41	12.6	191	11.6	0.2	6.7	5.0	79
	38	193	99	12.5	187	11.0	0.2	6.2	4.5	54
	39	114	55	9.7	181	10.9	0.1	6.4	4.8	40
	40	107	51	10.5	201	10.3	0.2	6.2	4.6	79
05	41	151	62	10.7	186	10.8	0.1	6.3	4.7	86
25	41 42	329	180	12.1	192	10.2	0.1	6.3	4.5	51
			47	9.5	188	10.2	0.1	6.5	4.8	99
	43	121	62	12.7	198	10.4	0.1	6.3	4.7	47
	44	185		11.5	190	10.6	0.1	6.0	4.4	45
	45	131	55	11.5	190	10.0	0.1	0.0	7.7	45
10	46	139	38	12.1	200	10.8	0.1	6.4	4.6	68
10	47	122	39	11.1	187	10.4	0.1	6.2	4.4	65
	48	115	43	11.0	191	11.2	0.1	6.5	4.7	100
	49	124	47	10.1	169	10.8	0.1	6.0	4.6	95
	50	118	62	10.7	205	10.7	0.1	6.0	4.3	69
										-
2.5	51	139	60	9.8	174	10.3	0.1	6.1	4.4	81
	52	113	45	11.1	204	10.9	0.1	6.2	4.5	70
	53	131	43	11.6	205	11.1	0.1	6.4	4.7	61
	54	152	61	11.3	184	10.2	0.1	6.2	4.5	72
	55	187	46	12.4	200	10.9	0.1	6.2	4.5	58
					407	40.4	0.1	6.0	4.5	72
0	56	149	55 47	9.6	187	10.4	0.1	6.0 6.3	4.6	40
	57 	121	47	10.7	198	10.9	0.1	6.4	4.6	101
	58	119	49	10.3	209	10.6	0.1	6.4 6.0	4.5	70
	59	140	69	10.8	186	10.4	0.1		4.5	86
	60	176	67	11.2	187	10.8	0.1	6.3	4.0	00

	•
	_
	•
	•
	_
	-
	•
	•
	=
	8
	_
	1
	=
	•
	1
	•

APPENDIX F CLINICAL OBSERVATIONS

Clinical Observations

<u>Date</u>	
6-21-94	All animals appear normal.
6-22-94	All animals appear normal.
6-23-94	All animals appear normal.
6-24-94	All animals appear normal.
6-27-94	All animals appear normal.
6-28-94	All animals appear normal except animal number 10-50 who has a scab associated with the implant site.
6-29-94	All animals appear normal.
6-30-94	All animals appear normal.
7-1-94	All animals appear normal.
7-5-94	All animals appear normal.
7-6-94	All animals appear normal.
7-7-94	All animals appear normal.

APPENDIX G

GROSS AND HISTOPATHOLOGY DATA

PROJECT SUMMARY

STUDY NUMBER: 94-003 STUDY ID : DNB Study FATE: ALL SEX: FEMALE | DAYS ON TEST: ALL INCIDENCE OF NEOPLASTIC and NON-NEOPLASTIC MICROSCOPIC FINDINGS 4 5 6 2 3 1 GROUP: 5 5 5 5 5 5 NUMBER OF ANIMALS: % % % # % # # 5 5 5 5 5 # EX 5 BRAIN 0 0.0 0.0 80.0 0 0.0 0 0.0 0 0.0 0 Vacuolization 0 0.0 0 0.0 0 0.0 0.0 0.0 4 80.0 0 Microgliosis 0.0 0 0.0 3 60.0 0 0.0 0 0.0 0 0.0 0 Necrosis 0.0 0 0.0 0 0.0 n 20.0 0.0 0.0 Hemorrhage 5 0 0 0 0 # EX 5 SCIATIC NERVE 0 0 5 0 # EX 5 SPINAL CORD 0 0 0 SALIVARY GLAND # EX 5 0 20.0 0.0 0.0 0.0 0 0.0 Inflammation, Chronic/Active 0 0 0 0 5 5 0 # EX **PANCREAS** 5 0 0 0 MANDIBULAR LYMPH NODE # EX 5 0 # EX 0 n 0 ZYMBAL'S GLAND 0 5 0 0 0 # EX **PITUITARY** 5 0 # FX 5 0 0 **ADRENALS** 5 0 # EX THYROID 0 0 # EX PARATHYROID 0 0 5 0 # EX 5 **TRACHEA** 5 0 0 0 # EX 0 **ESOPHAGUS**

Incidence Calculated by No. of Tissues Scored

PROJECT SUMMARY

STUDY ID : DNB Study FATE: ALL						STUDY A	NUMBER: 94-003
DAYS ON TEST: ALL INCIDENCE	OF NEOPLASTIC	and NON-NE	OPLASTIC MIC	ROSCOPIC FI	NDINGS		SEX: FEMALE
GROUP:		1	2	3	4	5	6
NUMBER OF ANIMALS:		5	5	5	5	5	5
		# %	# %	# %	# %	# %	# %
THYMUS	# EX	5	0	0	0	0	5
HEART	# EX	5	0	0	0	0	5
COLON	# EX	5	0	0	0	0	5
JEJUNUM	# EX	5	0	0	0	0	5
AORTA	# EX	5	0	0	0	0	5
LIVER	# EX	5	0	0	0	0	5
SPLEEN	# EX	5	5	5	5	5	5
Hyperplasia, Erythroid Cell		5 100.0	5 100.0	4 80.0	0.0	0.0	0.0
Pigmentation, NOS		5 100.0	5 100.0	0.0	0.0	0 0.0	0 0.0
Fibrosis		0 0.0	1 20.0	1 20.0	0 0.0	1 20.0	0 0.0
Depletion, Lymphoid		2 40.0	3 60.0	0 0.0	0.0	0.0	0 0.0
TONGUE	# EX	5	0	0	0	0	5
SKELETAL MUSCLE	# EX	5	0	0	0	0	5
LUNGS	# EX	5	0	0	0	0	5
Inflammation, Chronic		0.0	0 0.0	0 0.0	0.0	0 0.0	1 20.0
KIDNEYS	# EX	5	0	0	0	0	5
Mineralization, NOS		5 100.0	0 0.0	0 0.0	0 0.0	0 0.0	3 60.0
URINARY BLADDER	# EX	5	0	0	0	0	5

Incidence Calculated by No. of Tissues Scored

PROJECT SUMMARY

STUDY ID : DNB Study											STUDY	NUMBER:	94-1
ATE: ALL AYS ON TEST: ALL INCIDENCE	OF NEOPLASTIC	anc	I NON-NE	OPLAS	TIC MIC	ROSCOI	PIC FIN	DINGS				SEX:	FEM
GROUP:			1		2		3		4		5		6
NUMBER OF ANIMALS:			5		5		5		5		5		5
		#	%	#	%		%	#	%		%	#	%
STOMACH	# EX	5		0		0		0		0		5	
DUODENUM	# EX	5		0		0		0		0		5	
ILEUM	# EX	5		0		0		0		0		5	
CECUM	# EX	5		. 0		0		0		0		4	
RECTUM	# EX	5		0		0		0		0		5	
MESENTERIC LYMPH NODE	# EX	5		0		0		0		0		4	
OVARIES	# EX	5		1		0		0		0		5	
Cyst, NOS		0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0
JTERUS	# EX	5		0		0		0		0		5	
Dilatation, Bilateral		1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
skin	# EX	5		0		0		0		0		5	
CLITORAL GLAND	# EX	5		0		0		0		0		5	
Inflammation, Chronic/Active			60.0	0	0.0		0.0	0	0.0	0	0.0		40.0
Lymphocytic Infiltrates		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	40.0
EYES	# EX	5		0		0		0		0		5	
Microgranuloma, Cornea		1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
HARDERIAN GLAND	# EX	5		0		0		0		0		5	
		4	20.0	0	0.0	n	nη	n	n n	0	0.0	0	0.0

Incidence Calculated by No. of Tissues Scored

Lymphocytic Infiltrates

PROJECT SUMMARY

STUDY ID : DNB Study STUDY NUMBER: 94-003

FATE: ALL

DAYS ON TEST: ALL SEX: FEMALE

INCIDENCE OF N	NEOPLASTIC	and	NON-NEO	OPLAS	FIC MIC	ROSCO	PIC FIND	INGS					
GROUP:			1		2		3		4		5		6
NUMBER OF ANIMALS:			5		5		5		5		5		5
		#	%	#	%	#	%	#	%	#	%	#	%
FEMUR/STERNUM	# EX	5		0		0		0		0		5	
Hyperplasia, Erythroid Cell		5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NASAL	# EX	5		0		0		0		0		5	
MAMMARY GLAND	# EX	5		0		0		0		0		5	

Incidence Calculated by No. of Tissues Scored

PROJECT SUMMARY

				CT D) Litter	 								
STUDY ID : DNB Study							· · · · · ·					STUDY NU	JMBER	: 94-00
DAYS ON TEST: ALL			7										SI	EX: MALE
	INCIDENCE OF NEOPLA													
GROUP:				7		8		9		10		11		12
NUMBER OF ANIMALS:				5		5		5		5		5		5
				%	#	%	#	%	#	%	#	%	#	%
BRAIN	#	# EX	5		5		5		5		5	_	5	
Vacuolization				80.0		0.0	0	0.0	0	0.0	0		0	0.0
Microgliosis				80.0	0	0.0	0		0	0.0	0	0.0	0	0.0
Necrosis			4	80.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SCIATIC NERVE	#	# EX	5		0		0		0		0		5	
SPINAL CORD	#	# EX	5		0		0		0		0		5	
SALIVARY GLAND	#	# EX	5		0		0		0		0		5	
PANCREAS	#	# EX	5		0		0		0		0		5	
MANDIBULAR LYMPH NODE	#	# EX	5		2		0		0		0		5	
Hyperplasia, Lymphoid			2	40.0	1	50.0	0	0.0	0	0.0	0	0.0	1	20.0
Hemorrhage			0	0.0	2 '	100.0	0	0.0	0	0.0	0	0.0	0	0.0
ZYMBAL'S GLAND	#	# EX	5		0		0		0		0		5	
PITUITARY	#	# EX	3		0		0		0		0		5	
ADRENALS	#	# EX	5		0		0		0		0		5	
THYROID	#	# EX	5		0		0		0		0		5	
PARATHYROID	#	# EX	2		0		0		0		0		4	
TRACHEA	* · · · · · · · · · · · · · · · · · · ·	# EX	5		0		0		0		0		5	
ESOPHAGUS	#	# EX	5		0		0		0		0		5	

Incidence Calculated by No. of Tissues Scored

PROJECT SUMMARY

STUDY NUMBER: 94-003 STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL SEX: MALE INCIDENCE OF NEOPLASTIC and NON-NEOPLASTIC MICROSCOPIC FINDINGS GROUP: 8 9 10 11 12 5 5 5 NUMBER OF ANIMALS: % # % % % **THYMUS** # EX 5 0 0 0 0 5 0.0 0 0.0 0 0.0 1 20.0 0 0.0 0 0.0 0 Hemorrhage 5 0 0 # EX 0 0 **HEART** 0 0 0 5 COLON # EX 0 5 # EX 5 0 **JEJUNUM** 0 5 0 0 # EX **AORTA** 0 0 0 5 5 n LIVER # EX 5 # EX 5 5 5 5 **SPLEEN** 5 100.0 5 100.0 4 80.0 0 0.0 0 0.0 0.0 Hyperplasia, Erythroid Cell 0.0 Pigmentation, NOS 5 100.0 0.0 0.0 0 0.0 0 0.0 0 20.0 n 0.0 n 0.0 0 0.0 0.0 0.0 Fibrosis 0 0 5 **TONGUE** # EX 0 0 0 5 SKELETAL MUSCLE # EX 0 0 0 # EX 5 0 LUNGS 0 0.0 1 20.0 0 0.0 0 0.0 0 0.0 0 0.0 Inflammation, Chronic KIDNEYS # EX 5 5 100.0 5 100.0 5 100.0 5 100.0 5 100.0 5 100.0 Mineralization, NOS 0.0 0.0 0.0 5 100.0 4 80.0 1 20.0 0 Hyaline Droplets 1 20.0 4 80.0 3 60.0 1 20.0 3 60.0 3 60.0 Regeneration, Tubular 5 100.0 5 100.0 5 100.0 4 80.0 5 100.0 5 100.0

Incidence Calculated by No. of Tissues Scored

Degeneration, Tubular

PROJECT SUMMARY

STUDY ID : DNB Study FATE: ALL							NUMBER: 94-0
AYS ON TEST: ALL							SEX: MA
INCIDENCE OF 1	NEOPLASTIC	and NON-NE	OPLASTIC MICI	ROSCOPIC FIN	IDINGS		~~~~~
GROUP:		7	8	9	10	11	12
NUMBER OF ANIMALS:		5	5	5	5	5 	5
•••••		# %	# %	# %	# %	# %	# %
URINARY BLADDER	# EX	5	0	0	1	0	5
Urolith, NOS		2 40.0	0 0.0	0.0	0 0.0	0 0.0	0 0.0
PROSTATE	# EX	5	0	0	1	0	5
STOMACH	# EX	5	0	0	1	0	5
Inflammation, Chronic/Active		1 20.0	0 0.0	0 0.0	0 0.0	0 0.0	0 0.0
DUODENUM	# EX	5	0	0	1	0	5
ILEUM	# EX	5	0	0	1 1	0	5
CECUM	# EX	5	0	0	1	0	5
RECTUM	# EX	5	0	0 .	1	0	5
MESENTERIC LYMPH NODE	# EX	5	0	0	1	0	5
TESTES	# EX	5	5	5	5	5	5
Degeneration, Seminiferous Tubules	24 -	5 100.0	5 100.0	0 0.0	0 0.0	0 0.0	0 0.0
EPIDIDYMIDES	# EX	5	0	0	0	0	5
Hypospermia		5 100.0	0 0.0	0.0	0.0	0 0.0	0 0.0
SEMINAL VESICLE	# EX	5	0	0	0	0	5
SKIN	# EX	5	0	0	0	0	5
PREPUTIAL GLAND	# EX	5	0	0	0	0	5
Inflammation, Chronic/Active		1 20.0	0 0.0	0.0	0.0	0 0.0	0 0.0
Lymphocytic Infiltrates		2 40.0	0 0.0	0 0.0	0 0.0	0.0	4 80.0

Incidence Calculated by No. of Tissues Scored

PROJECT SUMMARY

STUDY ID : DNB Study STUDY NUMBER: 94-003

FATE: ALL

DAYS ON TEST: ALL SEX: MALE

INCIDENCE OF	NEOPLASTIC	and NON-NE	OPLASTIC MIC	ROSCOPIC FIN	DINGS		
GROUP: NUMBER OF ANIMALS:		7 5	8 5	9 5	10 5	11 5	12 5
EYES Microgranuloma, Cornea	# EX	# % 5 2 40.0	# % 0 0 0.0	# % 0 0 0.0	# % 0 0 0.0	# % 0 0 0.0	# % 5 1 20.0
HARDERIAN GLAND	# EX	5	0	0	0	0	5
FEMUR/STERNUM Hyperplasia, Erythroid Cell	# EX	5 5 100.0	0 0 0.0	0 0 0.0	0 0 0.0	0 0 0.0	5 0 0.0
NASAL	# EX	5	0	0	0	0	5
MAMMARY GLAND	# EX	5	0	0	0	0	5

Incidence Calculated by No. of Tissues Scored

(END OF REPORT)

SEVERITY SUMMARY

STUDY ID : DNB Study STUDY NUMBER: 94-06

STUDY ID : DNB Study						STUDY N	UMBER: 94-003
FATE: ALL DAYS ON TEST: ALL							SEX: FEMALE
GROUP:		1	2	3	4	5	6
NUMBER OF ANIMALS:		5	5	5	5	5	5
		# SEV	# SEV				
BRAIN	# EX	5	5	5	5	5	5
Vacuolization		4 1.40	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
Microgliosis		4 1.80	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
Necrosis		3 0.80	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
Hemorrhage		0 0.00	0 0.00	1 0.20	0 0.00	0 0.00	0 0.00
SCIATIC NERVE	# EX	5	0	0	0	0	5
SPINAL CORD	# EX	5	0 .	0	0	0	5
SALIVARY GLAND	# EX	5	0	0	0	0	5
Inflammation, Chronic/Active		0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 0.20
PANCREAS	# EX	5	0	0	0	0	5
MANDIBULAR LYMPH NODE	# EX	5	0	0	0	0	5
ZYMBAL'S GLAND	# EX	5	0	0	0	0	5
PITUITARY	# EX	4	0	0	0	0	5
ADRENALS	# EX	5	0	0	0	0	5
THYROID	# EX	5	0	0	0	0	5
PARATHYROID	# EX	5	0	0	0	0	4
TRACHEA	# EX	5	0	0	0	0	5
ESOPHAGUS	# EX	5	0	0	0	0	5

Severity Calculated by No. of Tissues Scored

SEVERITY SUMMARY

TUDY ID : DNB Study ATE: ALL						STUDY	IUMBER: 94-1
AYS ON TEST: ALL							SEX: FEM/
GROUP:		1	2	3	4	5	6
NUMBER OF ANIMALS:		5	5	5	5	5	5
		# SEV					
THYMUS	# EX	5	0	0	0	0	5
HEART	# EX	5	0	0	0	0	5
COLON	# EX	5	0	0	0	0	5
JEJUNUM	# EX	5	0	0	0	0	5
AORTA	# EX	5	0	0	0	0	5
IVER	# EX	5	0	0	0	0	5
SPLEEN	# EX	. 5	5	5	5	5	5
Hyperplasia, Erythroid Cell		5 2.80	5 3.20	4 1.00	0 0.00	0 0.00	0 0.00
Pigmentation, NOS		5 2.00	5 1.00	0 0.00	0 0.00	0 0.00	0 0.00
Fibrosis		0 0.00	1 0.20	1 0.40	0 0.00	1 0.20	0 0.00
Depletion, Lymphoid		2 0.60	3 1.00	0 0.00	0 0.00	0 0.00	0 0.00
TONGUE	# EX	5	0	0	0	0	5
SKELETAL MUSCLE	# EX	5	0	0	0	0	5
LUNGS	# EX	5	0	0	0	0	5
Inflammation, Chronic		0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 0.20
CIDNEYS	# EX	5	0	0	0	0	5
Mineralization, NOS		5 1.00	0 0.00	0 0.00	0 0.00	0 0.00	3 0.60
JRINARY BLADDER	# EX	5	0	0	0	0	5
STOMACH	# EX	5	0	0	0	0	5

Severity Calculated by No. of Tissues Scored

SEVERITY SUMMARY

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL						STUDY	NUMBER: 94-00
GROUP: NUMBER OF ANIMALS:		1 5	2 5	3 5	4 5	5 5	6 5
•		# SEV					
DUODENUM	# EX	5	0	0	0	0	5
ILEUM	# EX	5	0	0	0	0	5
CECUM	# EX	5	0	0	0	0	4
RECTUM	# EX	5	0	0	0	0	5
MESENTERIC LYMPH NODE	# EX	5	0	0	0	0	4
OVARIES	# EX	5	1	0	0	0	5
UTERUS	# EX	5	0	0	0	0	5
Dilatation, Bilateral		1 0.20	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SKIN	# EX	5	0	0	0	0	5
CLITORAL GLAND	# EX	5	0	0	0	0	5
Inflammation, Chronic/Active		3 0.80	0 0.00	0 0.00	0 0.00	0 0.00	2 0.60
Lymphocytic Infiltrates		0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	2 0.40
EYES	# EX	5	0	0	0	0	5
Microgranuloma, Cornea		1 0.20	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
HARDERIAN GLAND	# EX	5	0	0	0	0	5
Lymphocytic Infiltrates	₩ L A	1 0.20	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
FEMUR/STERNUM	# EX	5	0	0	0	0	5
Hyperplasia, Erythroid Cell		5 2.40	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NASAL	# EX	5	0	0	0	0	5

Severity Calculated by No. of Tissues Scored

SEVERITY	SUMMARY

STUDY ID : DNB Study						STUDY N	UMBER: 94-003
FATE: ALL DAYS ON TEST: ALL							SEX: FEMALE
GROUP: NUMBER OF ANIMALS:		1 5	2 5	3 5	4 5	5 5	6 5
MAMMARY GLAND	# EX	# SEV 5	# SEV 0	# SEV 0	# SEV 0	# SEV 0	# SEV 5

Severity Calculated by No. of Tissues Scored

(Report Continued)

SEVERITY SUMMARY

TUDY ID : DNB Study						STUDY N	IUMBER: 94-
ATE: ALL AYS ON TEST: ALL				·			SEX: M
GROUP:		7	8	9	10	11	12
NUMBER OF ANIMALS:		5	5	5	5	5	5
		# SEV					
BRAIN	# EX	5	5	5	5	5	5
Vacuolization		4 1.60	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
Microgliosis		4 1.80	0.00	0 0.00	0 0.00	0 0.00	0 0.00
Necrosis		4 1.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SCIATIC NERVE	# EX	5	0	0	0	0	5
SPINAL CORD	# EX	5	0	0	0	0	5
SALIVARY GLAND	# EX	5	0	0	0	0	5
PANCREAS	# EX	5	0	0	0	.0	5
MANDIBULAR LYMPH NODE	# EX	5	2	0	0	0	5
Hyperplasia, Lymphoid Hemorrhage		2 0.80 0 0.00	1 1.00 2 1.50	0 0.00 0 0.00	0 0.00 0 0.00	0 0.00 0 0.00	1 0.40 0 0.00
YMBAL'S GLAND	# EX	5	0	0	0	0	5
ITUITARY	# EX	3	0	0	0	0	5
DRENALS	# EX	5	0	0	0	0	5
HYROID	# EX	5	0	0	0	0	5
PARATHYROID	# EX	2	0	0	0	0	4
RACHEA	# EX	5	0	0	0	0	5
ESOPHAGUS	# EX	5	0	0	0	0	5

Severity Calculated by No. of Tissues Scored

SEVERITY SUMMARY

	SEV	/ERITY	SUMMARY				
STUDY ID : DNB Study FATE: ALL						STUDY N	NUMBER: 94-003
DAYS ON TEST: ALL							SEX: MALE
GROUP:		7	8	9	10	11	12
NUMBER OF ANIMALS:		5	5	5	5	5	5
		# SEV	# SEV	# SEV	# SEV	# SEV	# SEV
THYMUS	# EX	5	0	0	0	0	5
Hemorrhage		0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 0.20
HEART	# EX	5	0	0	0	0	5
COLON	# EX	5	0	0	0	0	5
JEJUNUM	# EX	5	0	0	0	0	5
AORTA	# EX	5	0	0	0	0	5
LIVER	# EX	5	0	0	0	0	5
SPLEEN	# EX	5	5	5	5	5	5
Hyperplasia, Erythroid Cell		5 3.00	5 3.00	4 1.40	0 0.00	0 0.00	0 0.00
Pigmentation, NOS		5 1.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
Fibrosis		0 0.00	0 0.00	1 0.20	0 0.00	0 0.00	0 0.00
TONGUE	# EX	5	0	0	0	0	5
SKELETAL MUSCLE	# EX	5	0	0	0	0	5
LUNGS	# EX	5	0	0	0	0	5
Inflammation, Chronic		0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 0.20
KIDNEYS	# EX	5	5	5	5	5	5
Mineralization, NOS		5 1.60	5 1.20	5 1.20	5 1.20	5 1.00	5 1.40
Hyaline Droplets		5 2.00	4 1.00	1 0.20	0 0.00	0 0.00	0 0.00
Regeneration, Tubular		3 1.00	3 0.60	4 0.80	3 0.60	1 0.20	1 0.20
Degeneration, Tubular		5 2.40	5 1.40	5 1.60	4 0.80	5 1.20	5 1.60

Severity Calculated by No. of Tissues Scored

SEVER	עידיד	SUMMARY	•

STUDY ID : DNB Study	• • • • • • • • • • • • • • • • • • • •					STUDY N	NUMBER: 94-003
FATE: ALL DAYS ON TEST: ALL							SEX: MALE
GROUP:		7	8	9	10	11	12
NUMBER OF ANIMALS:		5	5	5	5	5	5
		# SEV	# SEV				
URINARY BLADDER	# EX	5	0	0	1	0	5
PROSTATE	# EX	5	0	0	1	0	5
STOMACH	# EX	5	0	0	1	0	5
Inflammation, Chronic/Active		1 0.20	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
DUODENUM	# EX	5	0	0	1	0	5
ILEUM	# EX	5	0	0	1	0	5
CECUM	# EX	5	0	0	1	0	5
RECTUM	# EX	5	0	0	1	0	5
MESENTERIC LYMPH NODE	# EX	5	0	0	1	0	5
TESTES	# EX	5	5	5	5	5	5
Degeneration, Seminiferous Tubules		5 4.00	5 4.00	0 0.00	0 0.00	0 0.00	0 0.00
EPIDIDYMIDES	# EX	5	0	0	0	0	5
Hypospermia		5 4.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SEMINAL VESICLE	# EX	5	0	0	0	0	5
SKIN	# EX	5	0	0	0	0	5
PREPUTIAL GLAND	# EX	5	0	0	0	0	5
Inflammation, Chronic/Active		1 0.20	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
Lymphocytic Infiltrates		2 0.40	0 0.00	0 0.00	0 0.00	0 0.00	4 0.80

Severity Calculated by No. of Tissues Scored

SEVERITY SUMMARY

1	SE (/ERITI	SUMMAKI				
STUDY ID : DNB Study FATE: ALL						STUDY A	IUMBER: 94-003
DAYS ON TEST: ALL							SEX: MALE
GROUP:		7	8	9	10	11	12
NUMBER OF ANIMALS:		5	5	5	5	5	5
		# SEV	# SEV	# SEV	# SEV	# SEV	# SEV
EYES	# EX	5	0	0	0	0	5
Microgranuloma, Cornea		2 0.40	0 0.00	0 0.00	0 0.00	0 0.00	1 0.20
HARDERIAN GLAND	# EX	5	0	0	0	0	5
FEMUR/STERNUM	# EX	5	0	0	0	0	5
Hyperplasia, Erythroid Cell		5 2.40	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NASAL	# EX	5	0	0	0	0	5
MAMMARY GLAND	# EX	5	0	0	0	0	5

Severity Calculated by No. of Tissues Scored

(END OF REPORT)

Exposure in liberal 511 mass

	TABULATED AN	IMAL I				
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL						OY NUMBER: 94-003 GROUP: 1 SEX: FEMALE
ANIMAL ID:	1				5	
BRAIN	N					
Vacuolization	-	2	2		2	
Microgliosis	•	2	3	2	2	
Necrosis	•	•	2	1	1	
SCIATIC NERVE	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	
ALIVARY GLAND	N	N	N	N	N	
ANCREAS	N	N	N	N	N	
ANDIBULAR LYMPH NODE	N	N	N	N	N	
YMBAL'S GLAND	N	N	N	N	N	
ITUITARY	U	N	N	N	N	
DRENALS	. N	N	N	N	N	
HYROID	N	N	N	N	N	
ARATHYROID	N	N	N	N	N	
RACHEA	N	N	N	N	N	
SOPHAGUS	N	N	N	N	N	
HYMUS	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STUI	DY NUMBER: 94-003 GROUP: 1 SEX: FEMALE
ANIMAL ID:	1	2	3	4	5	
HEART	N	N	N	N	N	
COLON	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	
AORTA	N	N	N	N	N	
LIVER	N	N	N	N	N	
SPLEEN Hyperplasia, Erythroid Cell Pigmentation, NOS Depletion, Lymphoid	3 2 2	2 2 -	3 2 1	3 2 -	3 2 -	
TONGUE	N	N	N	N	N	
SKELETAL MUSCLE	N	N	N	N	N	
LUNGS	N	N	N	N	N	
KIDNEYS Mineralization, NOS	1	1	1	1	1	
URINARY BLADDER	N	N	N	N	N	
STOMACH	N	N	N	N	N	
DUODENUM	N	N	N	N	N	
ILEUM	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

Exposure in rischer 344 kaca

	TABULATED .	ANIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STU	DY NUMBER: 94-003 GROUP: 1 SEX: FEMALE
ANIMAL ID:	1	2			5	
CECUM	N	N	N	N	N	
RECTUM	N	N	N	N	N	
MESENTERIC LYMPH NODE	и	N	N	N	N	
OVARIES	и	N	N	N	N	
UTERUS Dilatation, Bilateral	N -	N -	N -	1	N -	
SKIN	N	N	N	N	N	
CLITORAL GLAND Inflammation, Chronic/Active	1	N -	N -	1	2	
EYES Microgranuloma, Cornea	1	N -	N -	N -	N -	
HARDERIAN GLAND Lymphocytic Infiltrates	N -	N -	N -	N -	1	
FEMUR/STERNUM Hyperplasia, Erythroid Cell	3	3	2	2	2	
NASAL	·N	N	N	N	N	
MAMMARY GLAND	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

TABIILATED A	ANTMAT.	DATA
--------------	---------	------

·	TABULATED AN	TWALL	UAIA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STL	DY NUMBER: 94-003 GROUP: 2 SEX: FEMALE
ANIMAL ID:	6	7	8	9	10	
BRAIN	N	N	N	N	N	
SCIATIC NERVE	*	*	*	*	*	
SPINAL CORD	*	*	*	*	*	
SALIVARY GLAND	•	*	*	*	*	
PANCREAS	*	*	*	*	*	
MANDIBULAR LYMPH NODE	*	*	*	*	*	
ZYMBAL'S GLAND	*	*	*	*	*	
PITUITARY	*	*	*	*	*	
ADRENALS	*	*	*	*	*	
THYROID	*	*	*	*	*	
PARATHYROID	•	*	*	*	*	
TRACHEA	•	*	*	*	*	
ESOPHAGUS	*	*	*	*	•	
THYMUS	*	*	*	*	*	
HEART	*	*	*	*	*	
COLON	•	*	*	*	*	

See Reports Code Table for Symbol Definitions

TADITATION ANTWAL DATA

	TABULATED	ANIMA				
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					SI	GROUP: 2 SEX: FEMALE
ANIMAL ID:	6		8		10	
JEJUNUM		*	* *	*	*	
AORTA		*	* *	*	*	
LIVER		*	* *	*	*	
SPLEEN				_		
Hyperplasia, Erythroid Cell			3 3		3	
Pigmentation, NOS		•	1 1		1	
Fibrosis			1 -		-	
Depletion, Lymphoid		2	2 1	-	•	
TONGUE		* 1	* *	*	*	
SKELETAL MUSCLE		* 1	* *	*	*	
LUNGS		* :	* *	*	*	
KIDNEYS		* 1	+ *	*	*	
URINARY BLADDER		* 1	* *	*	*	
STOMACH		* 1	* *	*	*	
DUODENUM		* 1	* *	*	*	
ILEUM		*	* *	*	*	
CECUM		* '	* *	*	*	
RECTUM		*	* *	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

		TABULATED	ANIMAL	DATA			
STUDY ID : DNB FATE: ALL DAYS ON TEST: A						s	TUDY NUMBER: 94-003 GROUP: 2 SEX: FEMALE
ANIMAL	ID:	6	7	8	9	10	
MESENTERIC LYMPH	NODE	*	*	*	*	*	
OVARIES		*	* *		*	*	
Cyst, NOS		-	-	P	-	-	
UTERUS		*	*	*	*	*	
SKIN		•	*	*	*	*	
CLITORAL GLAND		•	*	*	*	*	
EYES		•	r	*	*	*	
HARDERIAN GLAND		•	*	*	*	*	
FEMUR/STERNUM		•	*	*	*	*	
NASAL		•	*	*	*	*	
MAMMARY GLAND		•	. *	*	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA STUDY NUMBER: 94-003 STUDY ID : DNB Study GROUP: 3 FATE: ALL SEX: FEMALE DAYS ON TEST: ALL 11 12 13 14 15 ANIMAL ID: N BRAIN 1 Hemorrhage SCIATIC NERVE SPINAL CORD SALIVARY GLAND **PANCREAS** MANDIBULAR LYMPH NODE ZYMBAL'S GLAND **PITUITARY ADRENALS** THYROID PARATHYROID TRACHEA **ESOPHAGUS** THYMUS HEART

See Reports Code Table for Symbol Definitions

(REPORT CONTINUED)

COLON

 	TABULATED	ANIMAI	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					ST	UDY NUMBER: 94-003 GROUP: 3 SEX: FEMALE
ANIMAL ID:	11	12	13	14	15	
JEJUNUM	*	* *	*	*	*	
AORTA	•	* *	*	*	*	
LIVER	•	* *	*	*	*	
SPLEEN Hyperplasia, Erythroid Cell Fibrosis		2 1		1 -	N - -	
TONGUE	•	*	*	*	*	
SKELETAL MUSCLE	•		*	*	*	
LUNGS	•	*	. *	*	*	
KIDNEYS	•	*	*	*	*	
URINARY BLADDER	•	*	*	*	*	
STOMACH	•		*	*	*	
DUODENUM	•		*	*	*	
ILEUM	•	* *	*	*	*	
CECUM	*		*	*	*	
RECTUM	•		*	*	*	
MESENTERIC LYMPH NODE	•		*	*	*	

See Reports Code Table for Symbol Definitions

	TABULATED A	IMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					stu	DY NUMBER: 94-003 GROUP: 3 SEX: FEMALE
ANIMAL ID:	11	12	13	14	15	
OVARIES	*	*	*	*	*	
UTERUS	*	*	*	*	*	
SKIN	*	*	*	*	*	
CLITORAL GLAND	*	*	*	*	*	
EYES	*	*	*	*	*	
HARDERIAN GLAND	*	*	*	*	*	
FEMUR/STERNUM	*	*	*	*	*	
NASAL	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

(REPORT CONTINUED)

MAMMARY GLAND

TABULATED ANIMAL DATA

		IADULATED A	MITITAL	DAIA			
	STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					ST	UDY NUMBER: 94-003 GROUP: 4 SEX: FEMALE
	ANIMAL ID:	16	17	18	19	20	
	BRAIN	N	N	N	N	N	
_	SCIATIC NERVE	*	*	*	*	*	
,	SPINAL CORD	*	*	*	*	*	
	SALIVARY GLAND	*	*	*	*	*	
	PANCREAS	*	*	*	*	*	
	MANDIBULAR LYMPH NODE	*	*	*	*	*	
_	ZYMBAL'S GLAND	*	*	*	*	*	
	PITUITARY	*	*	*	*	*	
	ADRENALS	*	*	*	*	*	
	THYROID	*	*	*	*	*	
	PARATHYROID	*	*	*	*	*	
_	TRACHEA	*	*	*	*	*	
	ESOPHAGUS	*	*	*	*	*	
	THYMUS	*	*	*	*	*	
	HEART	*	*	*	*	*	
	COLON	*	*	*	*	* ,	

See Reports Code Table for Symbol Definitions

	TABULATED A	ANIMAL				·
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL						UDY NUMBER: 94-003 GROUP: 4 SEX: FEMALE
ANIMAL ID:	16		18		20	
JEJUNUM	*	*	*	*	*	
AORTA	*	*	*	*	*	
LIVER	*	*	*	*	*	
SPLEEN	N	N	N	N	N	
TONGUE	*	*	*	*	*	
SKELETAL MUSCLE	*	*	*	*	*	
LUNGS	*	*	*	*	*	
KIDNEYS	*	*	*	*	*	
URINARY BLADDER	*	*	*	*	*	
STOMACH	*	*	*	*	*	
DUODENUM	*	*	*	*	*	
ILEUM	*	*	*	*	*	
CECUM	*	*	*	*	*	
RECTUM	*	*	*	*	*	
MESENTERIC LYMPH NODE	*	*	*	*	*	
OVARIES	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

	INDULATED A	JIA TIMATI	DAIA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL						STUDY NUMBER: 94-003 GROUP: 4 SEX: FEMALE
ANIMAL ID:	16	17	18	19	20	
UTERUS	*	*	*	*	*	
SKIN	*	*	*	*	*	
CLITORAL GLAND	*	*	*	*	*	
EYES	*	*	*	*	*	
HARDERIAN GLAND	*	*	*	*	*	
FEMUR/STERNUM	*	*	*	*	*	
NASAL	*	*	*	*	*	
MAMMARY GLAND	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

ДА	.pobure am rae			 		
	TABULATED A	NIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STL	DY NUMBER: 94-003 GROUP: 5 SEX: FEMALE
ANIMAL ID:	21		23			
BRAIN	N	N	N	N	N	
SCIATIC NERVE	*	*	*	*	*	
SPINAL CORD	*	*	*	*	*	
SALIVARY GLAND	*	*	*	*	*	
PANCREAS	*	*	*	*	*	
MANDIBULAR LYMPH NODE	*	*	*	*	*	
ZYMBAL'S GLAND	*	*	*	*	*	
PITUITARY	*	*	*	*	*	
ADRENALS	*	*	*	*	*	
THYROID	*	*	*	*	*	
PARATHYROID	*	*	*	*	*	
TRACHEA	*	*	*	*	*	
ESOPHAGUS	*	*	*	*	*	
THYMUS	*	*	*	*	*	
HEART	*	*	*	*	*	
COLON	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL ANIMAL ID:					STU	JDY NUMBER: 94-003
						GROUP: 5 SEX: FEMALE
	21	22	23	24	25	
JEJUNUM	*	*	*	*	*	
AORTA	*	*	*	*	*	
LIVER	*	*	*	*	*	
SPLEEN Fibrosis	1	N -	N -	N -	N -	
TONGUE	*	*	*	*	*	
SKELETAL MUSCLE	*	*	*	*	*	
LUNGS	*	*	*	*	*	
KIDNEYS	*	*	*	*	*	
URINARY BLADDER	*	*	*	*	*	
STOMACH	*	*	*	*	*	
DUODENUM	*	*	*	*	*	
ILEUM	*	*	*	*	*	
CECUM	*	*	*	*	*	
RECTUM	*	*	*	*	*	
MESENTERIC LYMPH NODE	*	*	*	*	*	
OVARIES	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

	TABULATED AN	IIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL			·		STU	OY NUMBER: 94-003 GROUP: 5 SEX: FEMALE
ANIMAL ID:	21	22	23	24	25	
UTERUS	*	*	*	*	*	
SKIN	*	*	*	*	*	
CLITORAL GLAND	*	*	.*	*	*	
YES	*	*	*	*	*	
HARDERIAN GLAND	*	*	*	*	*	
FEMUR/STERNUM	*	*	*	. *	*	
IASAL	*	*	*	*	*	
MAMMARY GLAND	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

TARDGATED ANIMAG DAT	ED ANIMAL DATA	ANTMAT.	ATED	RIII	TΆ
----------------------	----------------	---------	------	------	----

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					s	TUDY NUMBER: 94-003 GROUP: 6 SEX: FEMALE
ANIMAL ID:	26	27	28	29	30	•
BRAIN	N	N	N	N	N	
SCIATIC NERVE	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	
SALIVARY GLAND Inflammation, Chronic/Active	. 1	N -	· N -	N -	N -	
PANCREAS	N	N	N	N	· N	
MANDIBULAR LYMPH NODE	N	N	N	N	N	
ZYMBAL'S GLAND	N	N	N	N	N	
PITUITARY	N	N	N	N	N	
ADRENALS	N N	N	N	N	N	
THYROID	N	N	N	N	N	
PARATHYROID	N	N	U	N	N	
TRACHEA	N	N	N	N	N	
ESOPHAGUS	N	N	N	N	N	
THYMUS	N	N	N	N	N	
HEART	N	N	N	N	N	
COLON	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

	TABULATED	ANIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					s	TUDY NUMBER: 94-003 GROUP: 6 SEX: FEMALE
ANIMAL ID:	26	27	28	29	30	
EJUNUM		N N	N	N	N	
ORTA		N N	N	N	N	

DATO ON TESTS ACC		-				
ANIMAL ID:	26	27	28	29	30	
JEJUNUM	N	N	N	N	N	
AORTA	N	N	N	N	N	
LIVER	N	N	N	N	N	
SPLEEN	N	N	N	N	N	
TONGUE	N	N	N	, N	N	
SKELETAL MUSCLE	N	N	N	N	N	
LUNGS Inflammation, Chronic	N -	N -	N -	N -	1	
KIDNEYS Mineralization, NOS	1	1	N -	N -	1	
URINARY BLADDER	N	N	N	N	N	
STOMACH	N	N	N	N	N	
DUODENUM	N	N	N	N	N	
ILEUM	N	N	· N	N	N	
CECUM	N	N	Ņ	A	N	
RECTUM	· N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	N	N	U	

See Reports Code Table for Symbol Definitions

ጥአ	RIII	. א ידי א	תים	ZΝ	JTN	۸AT.	DATA

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STU	DY NUMBER: 94-003 GROUP: 6 SEX: FEMALE
ANIMAL ID:	26	27	28	29	30	
OVARIES	N	N	N	N	N	
UTERUS	N	N	N	N	N	
SKIN	N	N	N	N	N	
CLITORAL GLAND Inflammation, Chronic/Active Lymphocytic Infiltrates	2 -	- 1	N - -	- 1	1 -	
EYES	N	N	N	N	N	
HARDERIAN GLAND	N	N	N	N	N	
FEMUR/STERNUM	N	N	N	N	N	
NASAL	N	N	N	N	N	
MAMMARY GLAND	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

(Report Continued)

IMAL 1	DATA
	TWWT:

	TABULATED A	ANIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					!	STUDY NUMBER: 94-003 GROUP: 7 SEX: MALE
ANIMAL ID:	31	32	33	34	35	
BRAIN			N			
Vacuolization	. 1	2	-	3	2	
Microgliosis	2	2	-	3	2	
Necrosis	1	1	-	2	1	
SCIATIC NERVE	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	
SALIVARY GLAND	N	N	N	N	N	
PANCREAS	N	N	N	N	N	
AND ADDITION OF THE PROPERTY O	. N	N		N		
MANDIBULAR LYMPH NODE Hyperplasia, Lymphoid	-	-	2	-	2	
ZYMBAL'S GLAND	N	N	N	N	N	
PITUITARY	N	U	U	N	N	
ADRENALS	N	N	N	N	N	
THYROID	N	N	N	N	N	
PARATHYROID	U	N	υ	N	U	
TRACHEA	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

(REPORT CONTINUED)

ESOPHAGUS

TABULATED ANIMAL DATA

<u>.</u>	INDUNITED IN					
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STUD	Y NUMBER: 94-003 GROUP: 7 SEX: MALE
ANIMAL ID:	31	32	33	34	35	
THYMUS	N	N	N	N	N	
HEART	N	N	N	N	N	
COLON	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	
AORTA	N	N	N	N	N	
LIVER	N	N	N	N	N	
SPLEEN Hyperplasia, Erythroid Cell Pigmentation, NOS	3 1	3 1	3 1	3 1	3 1	
TONGUE	N	N	N	N	N	
SKELETAL MUSCLE	N	N	N	N	N	
LUNGS	N	N	N	N	N	
KIDNEYS						
Mineralization, NOS	2	2	2	1	1	
Hyaline Droplets	2	2	2	2	2	
Regeneration, Tubular	2	-	2	-	1	
Degeneration, Tubular	3	3	2	2	2	
URINARY BLADDER	N			N	N	
Urolith, NOS	-	P	Р	•	-	
PROSTATE	. N	N	N	N	N	

See Reports Code Table for Symbol Definitions

	TABULATED	ANIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STUDY	NUMBER: 94-003 GROUP: 7 SEX: MALE
ANIMAL ID:	31	32	33	34	35	

ANIMAL ID:	31	32	33	34	35
STOMACH		N	N	N	N
Inflammation, Chronic/Active	1	•	-	•	-
DUODENUM	N	N	N	N	N
ILEUM	N	N	N	N	N
CECUM	N	N	N	N	N
RECTUM	N	N	N	N	N
MESENTERIC LYMPH NODE	Ņ	N	N	N	N
TESTES Degeneration, Seminiferous Tubules	4	4	4	4	4
EPIDIDYMIDES Hypospermia	4	4	4	4	4
SEMINAL VESICLE	N	N	N	N	N
SKIN	N	N	N	N	N
PREPUTIAL GLAND	N				N
Inflammation, Chronic/Active Lymphocytic Infiltrates	. •	1 -	1	- 1	-
EYES		N	N	N	
Microgranuloma, Cornea	1	•	-	•	1
HARDERIAN GLAND	N	N	N	N	N .

See Reports Code Table for Symbol Definitions

TARIII	משידע.	ANIMAL	בדבת

•				. 		
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STU	OY NUMBER: 94-003 GROUP: 7 SEX: MALE
ANIMAL ID:	31	32	33	34	35	
FEMUR/STERNUM Hyperplasia, Erythroid Cell	2	3	2	2	3	
NASAL	N	N	N	N	N	
MAMMARY GLAND	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

	TABULATED	ANIMAL				
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					ST	UDY NUMBER: 94-003 GROUP: 8 SEX: MALE
ANIMAL ID:	36			39		
BRAIN		N N	N	N	N	
SCIATIC NERVE		* *	*	*	*	
SPINAL CORD		* *	*	*	*	
SALIVARY GLAND		* *	*	*	*	
PANCREAS		* *	*	*	*	
MANDIBULAR LYMPH NODE Hyperplasia, Lymphoid		* *	2	- 2	* -	
Hemorrhage ZYMBAL'S GLAND		* *	*	*	*	
PITUITARY		* *	*	*	*	
ADRENALS		* *	*	*	*	
THYROID		* *	*	*	*	
PARATHYROID		* *	*	*	*	
TRACHEA		* *	*	*	*	
ESOPHAGUS		* *	*	*	*	
THYMUS		* *	*	*	*	
HEART		* *	*	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					S	TUDY NUMBER: 94-003 GROUP: 8 SEX: MALE
ANIMAL ID:	36	37	38	39	40	
COLON	*	*	*	*	*	
JEJUNUM	*	*	*	*	*	
AORTA	*	*	*	*	*	
LIVER	*	*	*	*	*	
SPLEEN						
Hyperplasia, Erythroid Cell	3	3	3	3	3	
TONGUE	*	*	*	*	*	
SKELETAL MUSCLE	*	*	*	*	*	
LUNGS	*	*	*	*	*	
KIDNEYS						
Mineralization, NOS	1	1	2	1	1	
Hyaline Droplets	1	1	2	1	-	
Regeneration, Tubular	1	-	1	1	-	
Degeneration, Tubular	1	2	2	1	1	
URINARY BLADDER	*	*	*	*	*	
PROSTATE	*	*	*	*	*	
STOMACH	*	*	*	*	*	
DUODENUM	*	*	*	*	*	
ILEUM	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA STUDY NUMBER: 94-003 STUDY ID : DNB Study GROUP: 8 FATE: ALL SEX: MALE DAYS ON TEST: ALL 36 38 39 40 37 ANIMAL ID: CECUM RECTUM MESENTERIC LYMPH NODE **TESTES** Degeneration, Seminiferous Tubules **EPIDIDYMIDES** SEMINAL VESICLE SKIN PREPUTIAL GLAND **EYES** HARDERIAN GLAND FEMUR/STERNUM NASAL

See Reports Code Table for Symbol Definitions

(REPORT CONTINUED)

MAMMARY GLAND

TARIII ATED AN	TMAT. D	ል ሞል
----------------	---------	-------------

ABULATED AN	ITMAL I	DATA			
				STU	DY NUMBER: 94-003 GROUP: 9 SEX: MALE
41	42	43	44	45	
N	N	N	N	N	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
*	*	*	*	*	
	41 N * * * * * * * * * *	41 42 N N * * * * * * * * * * * * * * * * * *	N N N * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *	41 42 43 44 N N N N * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *	\$TU 41 42 43 44 45 N N N N N N * * * * * * * * * * * * * *

See Reports Code Table for Symbol Definitions

	TABULATED	ANIMAI	DATA			
						DV NUMBER - 0/ .007
STUDY ID : DNB Study					510	DY NUMBER: 94-003 GROUP: 9
FATE: ALL DAYS ON TEST: ALL						SEX: MALE
ANIMAL ID:	41	42	43	44	45	
JEJUNUM		* *	*	*	*	
AORTA		* *	*	*	*	
LIVER		* . *	*	*	* -	
SPLEEN					N	
Hyperplasia, Erythroid Cell		2 2	2	1	-	
Fibrosis			-	1	-	
TONGUE		* *	*	*	*	
SKELETAL MUSCLE		* *	*	*	*	
LUNGS		* *	*	*	*	
KIDNEYS						
Mineralization, NOS		2 1	1	1	1	
Hyaline Droplets		1 -	-	-	-	
Regeneration, Tubular		1 1	1	-	1	
Degeneration, Tubular	;	2 1	2	2	1	
JRINARY BLADDER	,	* *	*	*	*	
PROSTATE	,	* *	*	*	*	
TOMACH	,	* *	*	*	*	
DUODENUM	,	* *	*	*	*	
LEUM	,	* *	*	. *	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

.	TABULATED AN	ILMAL I	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STUD	Y NUMBER: 94-003 GROUP: 9 SEX: MALE
ANIMAL ID:	41	42	43	44	45	
CECUM	*	*	*	*	*	
RECTUM	*	*	*	*	*	
MESENTERIC LYMPH NODE	*	*	*	*	*	
TESTES	N	N	N	N	N	
EPIDIDYMIDES	*	*	*	*	*	
SEMINAL VESICLE	*	*	*	*	*	
SKIN	*	*	*	*	*	
PREPUTIAL GLAND	*	*	*	*	*	
EYES	*	,*	*	*	*	
HARDERIAN GLAND	*	*	*	*	*	
FEMUR/STERNUM	*	*	*	*	*	
NASAL	*	*	*	*	*	
MAMMARY GLAND	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

	TABULATED A	NIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL						Y NUMBER: 94-003 GROUP: 10 SEX: MALE
ANIMAL ID:			48		50	
BRAIN	N	N	N	N	N	
SCIATIC NERVE	*	*	*	*	*	
SPINAL CORD	*	*	*	*	*	
SALIVARY GLAND	*	*	. *	*	*	
PANCREAS	*	*	*	*	*	
MANDIBULAR LYMPH NODE	*	*	*	*	*	
ZYMBAL'S GLAND	*	*	*	*	*	
PITUITARY	*	*	*	*	*	
ADRENALS	*	*	*	*	*	
THYROID	*	*	*	*	*	
PARATHYROID	*	*	*	*	*	
TRACHEA	*	*	*	*	*	
ESOPHAGUS	*	*	*	*	*	
THYMUS	*	*	*	*	*	
HEART	*	*	*	*	*	
COLON	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					•	STUDY NUMBER: 94-00 GROUP: 1 SEX: MAL
ANIMAL ID:	46	47	48	49	50	
IEJUNUM	*	*	*	*	*	
AORTA	*	*	*	*	*	
IVER	*	*	*	*	*	
SPLEEN	N	N	N	N	N	
ONGUE	*	*	*	*	*	
SKELETAL MUSCLE	*	*	*	*	*	
ungs	*	*	*	*	*	
CIDNEYS						
Mineralization, NOS	1	1	2	1	1	
Regeneration, Tubular	1	1	1	-	-	
Degeneration, Tubular	1	1	1	-	1	
URINARY BLADDER	*	*	*	N	*	
PROSTATE	*	*	*	N	*	
STOMACH	*	*	*	N	*	
DUODENUM	*	*	*	N	*	
TLEUM	*	*	*	N	*	
CECUM	*	*	*	N	*	
RECTUM	*	*	*	N	*	

See Reports Code Table for Symbol Definitions

	TABULATED AN	IMAL :	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STUD	Y NUMBER: 94-003 GROUP: 10 SEX: MALE
ANIMAL ID:	46	47	48	49	50	
MESENTERIC LYMPH NODE	*	*	*	N	*	
TESTES	N	N	N	N	N	
EPIDIDYMIDES	*	*	*	*	*	
SEMINAL VESICLE	*	*	*	*	*	
SKIN	*	*	*	*	*	
PREPUTIAL GLAND	*	*	*	*	*	
EYES	*	*	*	*	*	
HARDERIAN GLAND	*	*	*	*	*	
FEMUR/STERNUM	*	*	*	*	*	
NASAL	*	*	*	*	*	
MAMMARY GLAND	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

		TABULATED A	NTWAL	DATA			
	STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL						STUDY NUMBER: 94-003 GROUP: 11 SEX: MALE
	ANIMAL ID:	51	52	53	54	55	
	BRAIN	N	N	N	N	N	
_	SCIATIC NERVE	*	*	*	*	*	
	SPINAL CORD	*	*	*	*	*	
	SALIVARY GLAND	*	*	*	*	*	
	PANCREAS	*	*	*	*	*	
	MANDIBULAR LYMPH NODE	*	*	*	*	*	
	ZYMBAL'S GLAND	*	*	*	*	*	
	PITUITARY	*	*	*	*	*	
	ADRENALS	*	*	*	*	*	
	THYROID	*	*	*	*	*	
	PARATHYROID	*	*	*	*	*	
	TRACHEA	*	*	*	*	*	
	ESOPHAGUS	*	*	*	*	*	
	THYMUS	*	*	*	*	*	
	HEART	*	*	•	*	*	
	COLON	*	*	*	*	*	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA STUDY NUMBER: 94-003 STUDY ID : DNB Study GROUP: 11 FATE: ALL SEX: MALE DAYS ON TEST: ALL 55 52 ANIMAL ID: **JEJUNUM** AORTA LIVER SPLEEN **TONGUE** SKELETAL MUSCLE LUNGS KIDNEYS 1 Mineralization, NOS Regeneration, Tubular Degeneration, Tubular URINARY BLADDER **PROSTATE** STOMACH DUODENUM ILEUM CECUM RECTUM

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

STUDY ID: DNB Study

FATE: ALL

DAYS ON TEST: ALL

ANIMAL ID:

STUDY NUMBER: 94-003

GROUP: 11

SEX: MALE

ANIMAL ID:	51	52	53	54	55
MESENTERIC LYMPH NODE	*	*	*	*	*
TESTES	N	N	N	N	N
EPIDIDYMIDES	*	*	*	*	*
SEMINAL VESICLE	*	*	*	*	*
SKIN	*	*	*	*	*
PREPUTIAL GLAND	*	*	*	*	*
EYES	*	*	*	*	*
HARDERIAN GLAND	*	*	*	*	*
FEMUR/STERNUM	*	*	*	*	*
NASAL	*	*	*	*	*
MAMMARY GLAND	*	*	*	*	*

See Reports Code Table for Symbol Definitions

	מידי ב	ABULA	מישידי	ANTMA	L DATA
--	--------	-------	--------	-------	--------

	TABULATED A	NIMAL	DATA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL						JDY NUMBER: 94-003 GROUP: 12 SEX: MALE
ANIMAL ID:	56	57	58	59	60	
BRAIN	N	N	N	N	N	
SCIATIC NERVE	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	
SALIVARY GLAND	. N	N	N	N	N	
PANCREAS	N	N	N	N	N	
MANDIBULAR LYMPH NODE Hyperplasia, Lymphoid	N -	N -	N -	N -	2	
ZYMBAL'S GLAND	. N	N	N	N	N	
PITUITARY	N	N	N	N	N	
ADRENALS	N	N	N	N	N	
THYROID	N	N	N	N	N	
PARATHYROID	N	N	U	N	N	
TRACHEA	N	N	N	N	N	
ESOPHAGUS	N	N	N	N	N	
THYMUS Hemorrhage	N -	N -	1	N -	N -	
HEART	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

TARIT.	מידים.	ANIMAL	מדגמ

STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STUD	Y NUMBER: 94-003 GROUP: 12 SEX: MALE
ANIMAL ID:	56	57	58	59	60	
COLON	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	
AORTA	N	N	N	N	N	
LIVER	N	N	N	N	N	
SPLEEN	N	N	N	N	N	
TONGUE	N	N	N	N	N	
SKELETAL MUSCLE	N	N	N	N	N	
LUNGS Inflammation, Chronic	N -	N -	N -	1	N -	
KIDNEYS						
Mineralization, NOS	2	1	2	1	1	
Regeneration, Tubular Degeneration, Tubular	- 1	1 1	2	2	2	
URINARY BLADDER	N	N	N	N	N	
PROSTATE	N	N	N	N	N	
STOMACH	N	N	N	N	N	
DUODENUM	N	N	N	N	N	
ILEUM	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

TABULATED ANIMAL DATA

	INDODUTED W	، الكليان	DAIA			
STUDY ID : DNB Study FATE: ALL DAYS ON TEST: ALL					STI	UDY NUMBER: 94-003 GROUP: 12 SEX: MALE
ANIMAL ID:	56	57	58	59	60	
CECUM	N	N	N	N	N	
RECTUM	N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	N	N	N	
TESTES	N	N	N	N	N	
EPIDIDYMIDES	N	N	N	N	N	
SEMINAL VESICLE	N	N	N	N	N	
SKIN	N	N	N	Ñ	N	
PREPUTIAL GLAND Lymphocytic Infiltrates	1	1	N -	1	1	
EYES Microgranuloma, Cornea	N -	N -	N -	N -	1	
HARDERIAN GLAND	N	N	N	N	N	
FEMUR/STERNUM	N	N	N	N	N	
NASAL	N	N	N	N	N	
MAMMARY GLAND	N	N	N	N	N	

See Reports Code Table for Symbol Definitions

(END OF REPORT)

CORRELATION OF GROSS & MICRO

.....

STUDY ID : DNB Study

STUDY NUMBER: 94-003

FATE: ALL

GROUP: 1

DAYS ON TEST: ALL

SEX: FEMALE

Animal ID: 5

Pathologist: GRO

Animal Fate: Terminal Sacrifice

Days on Test: 14

Reference to Necropsy Record: SPLEEN - Enlarged, Mild

Related Histopathology: SPLEEN - Hyperplasia, Erythroid Cell

CORRELATION OF GROSS & MICRO STUDY NUMBER: 94-003 STUDY ID : DNB Study GROUP: 2 FATE: ALL SEX: FEMALE DAYS ON TEST: ALL Pathologist: GRO Days on Test: 14 Animal Fate: Terminal Sacrifice Related Histopathology: Reference to Necropsy Record: SPLEEN - Hyperplasia, Erythroid Cell SPLEEN - Enlarged, Mild Pathologist: GRO Animal ID: 8 Days on Test: 14 Animal Fate: Terminal Sacrifice Related Histopathology: Reference to Necropsy Record: SPLEEN - Hyperplasia, Erythroid Cell SPLEEN - Enlarged, Mild OVARIES - Cyst, NOS OVARIES - Left, Cyst, 3mm, Round, Yellowish, Liquid

CORRELATION OF GROSS & MICRO

STUDY ID : DNB Study

FATE: ALL

STUDY NUMBER: 94-003

GROUP: 3

DAYS ON TEST: ALL SEX: FEMALE

(REPORT CONTINUED)

No Gross Observations for any animal in this group

Pathology Associates, Inc. Study Number 94-003 14 Day 1,3-Dinitrobenzene Exposure in Fischer 344 Rats

CORRELATION OF GROSS & MICRO

STUDY ID : DNB Study

FATE: ALL

DAYS ON TEST: ALL

SEX: FEMALE

No Gross Observations for any animal in this group

Pathology Associates, Inc. Study Number 94-003 14 Day 1,3-Dinitrobenzene Exposure in Fischer 344 Rats

CORRELATION OF GROSS & MICRO

STUDY ID : DNB Study

STUDY NUMBER: 94-003

FATE: ALL

GROUP: 5

DAYS ON TEST: ALL

SEX: FEMALE

No Gross Observations for any animal in this group

Pathology Associates, Inc. Study Number 94-003 14 Day 1,3-Dinitrobenzene Exposure in Fischer 344 Rats

CORRELATION OF GROSS & MICRO

STUDY ID : DNB Study

FATE: ALL

DAYS ON TEST: ALL

CORRELATION OF GROSS & MICRO

STUDY NUMBER: 94-003

GROUP: 6

SEX: FEMALE

No Gross Observations for any animal in this group

(Report Continued)

CORRELATION OF GROSS & MICRO

______ STUDY NUMBER: 94-003

STUDY ID : DNB Study

GROUP: 7

FATE: ALL

DAYS ON TEST: ALL

SEX: MALE

Pathologist: GRO Animal ID: 31

.....

Animal Fate: Terminal Sacrifice

Days on Test: 14

Reference to Necropsy Record: SPLEEN - Enlarged, Moderate

Related Histopathology:

SPLEEN - Hyperplasia, Erythroid Cell

TESTES - Bilateral, Decreased in size, Moderate

TESTES - Degeneration, Seminiferous Tubules

Pathologist: GRO

Animal Fate: Terminal Sacrifice

Days on Test: 14

Reference to Necropsy Record:

Related Histopathology:

SPLEEN - Enlarged, Moderate

SPLEEN - Hyperplasia, Erythroid Cell

TESTES - Bilateral, Decreased in size, Moderate

TESTES - Degeneration, Seminiferous Tubules

Animal ID: 33

Animal ID: 32

Animal Fate: Terminal Sacrifice

Pathologist: GRO

Days on Test: 14

Reference to Necropsy Record:

SPLEEN - Enlarged, Moderate

Related Histopathology:

SPLEEN - Hyperplasia, Erythroid Cell

TESTES - Bilateral, Decreased in size, Moderate TESTES - Degeneration, Seminiferous Tubules

CORRELATION OF GROSS & MICRO STUDY NUMBER: 94-003 STUDY ID : DNB Study GROUP: 7 FATE: ALL SEX: MALE DAYS ON TEST: ALL Pathologist: GRO Animal ID: 34 Days on Test: 14 Animal Fate: Terminal Sacrifice Related Histopathology: Reference to Necropsy Record: SPLEEN - Hyperplasia, Erythroid Cell SPLEEN - Enlarged, Moderate TESTES - Degeneration, Seminiferous Tubules TESTES - Bilateral, Decreased in size, Moderate Pathologist: GRO Animal ID: 35 Days on Test: 14 Animal Fate: Terminal Sacrifice Related Histopathology: Reference to Necropsy Record: SPLEEN - Hyperplasia, Erythroid Cell SPLEEN - Enlarged, Moderate TESTES - Degeneration, Seminiferous Tubules TESTES - Bilateral, Decreased in Size, Moderate

CORRELATION OF GROSS & MICRO STUDY NUMBER: 94-003 STUDY ID : DNB Study GROUP: 8 FATE: ALL DAYS ON TEST: ALL SEX: MALE Pathologist: GRO Animal ID: 36 Days on Test: 14 Animal Fate: Terminal Sacrifice Reference to Necropsy Record: Related Histopathology: SPLEEN - Hyperplasia, Erythroid Cell SPLEEN - Enlarged, Moderate TESTES - Bilateral, Decreased in Size, Moderate TESTES - Degeneration, Seminiferous Tubules Pathologist: GRO Animal ID: 37 Days on Test: 14 Animal Fate: Terminal Sacrifice Related Histopathology: Reference to Necropsy Record: SPLEEN - Enlarged, Mild SPLEEN - Hyperplasia, Erythroid Cell TESTES - Degeneration, Seminiferous Tubules TESTES - Bilateral, Decreased in Size, Moderate Pathologist: GRO Animal ID: 38 Days on Test: 14 Animal Fate: Terminal Sacrifice Reference to Necropsy Record: Related Histopathology: SPLEEN - Hyperplasia, Erythroid Cell SPLEEN - Enlarged, Moderate TESTES - Degeneration, Seminiferous Tubules TESTES - Bilateral, Decreased in size, Moderate MANDIBULAR LYMPH NODE - Foci, >1mm, Multiple, Red MANDIBULAR LYMPH NODE - Hemorrhage

CORRELATION OF GROSS & MICRO STUDY NUMBER: 94-003 STUDY ID : DNB Study GROUP: 8 FATE: ALL SEX: MALE DAYS ON TEST: ALL Pathologist: GRO Animal ID: 39 Days on Test: 14 Animal Fate: Terminal Sacrifice Related Histopathology: Reference to Necropsy Record: TESTES - Degeneration, Seminiferous Tubules TESTES - Bilateral, Decreased in size, Moderate MANDIBULAR LYMPH NODE - Foci, >1mm, Multiple, Red MANDIBULAR LYMPH NODE - Hemorrhage Pathologist: GRO Animal ID: 40 Days on Test: 14 Animal Fate: Terminal Sacrifice Related Histopathology: Reference to Necropsy Record: SPLEEN - Hyperplasia, Erythroid Cell SPLEEN - Enlarged, Moderate TESTES - Degeneration, Seminiferous Tubules TESTES - Bilateral, Decreased in size, Moderate

Pathology Associates, Inc. Study Number 94-003 14 Day 1,3-Dinitrobenzene Exposure in Fischer 344 Rats

CORRELATION OF GROSS & MICRO

STUDY ID : DNB Study

STUDY NUMBER: 94-003

FATE: ALL

GROUP: 9

DAYS ON TEST: ALL

SEX: MALE

No Gross Observations for any animal in this group

	CORRELATION	OF GRO	oss &	MICRO	
STUDY ID : DNB Study					STUDY NUMBER: 94-003
FATE: ALL					GROUP: 10
DAYS ON TEST: ALL					SEX: MALE

No Gross Observations for any animal in this group

CORRELATION OF GROSS & MICRO

STUDY ID : DNB Study

STUDY NUMBER: 94-003

FATE: ALL

GROUP: 11

DAYS ON TEST: ALL

SEX: MALE

No Gross Observations for any animal in this group

CORRELATION OF GROSS & MICRO

STUDY ID: DNB Study
FATE: ALL
DAYS ON TEST: ALL

CORRELATION OF GROSS & MICRO

STUDY NUMBER: 94-003
GROUP: 12
SEX: MALE

No Gross Observations for any animal in this group

(END OF REPORT)

APPENDIX H CHEMICAL ANALYSES

Determination of Homogeneity of DNB in the Diet

Target Concentration (mg/kg diet)	Site of Sampling	Concentration by Analysis (mg/kg diet)	Mean Concentration (mg/kg diet)	Deviation from Mean (%)
		WEEK 1		
	Top	152		0.97
150	Middle	153	151	1.64
	Bottom	147		2.61
	Top	75.7		0.93
75	Middle	74.9	75.0	0.05
, 0	Bottom	74.3		0.88
	Top	24.0		0.90
25	Middle	24.2	23.8	1.49
	Bottom	23.2		2.40
	Top	10.2		0.81
10	Middle	10.1	10.1	0.03
- 0	Bottom	10.0		0.83
	Top	2.69		4.29
2.5	Middle	2.50	2.58	3.02
	Bottom	2.55		1.27

Determination of Homogeneity of DNB in the Diet

Target Concentration (mg/kg diet)	Site of Sampling	Concentration by Analysis (mg/kg diet)	Mean Concentration (mg/kg diet)	Deviation from Mean (%)
		WEEK 2		
150	Top Middle Bottom	154 155 147	152	1.34 2.01 3.35
75	Top Middle Bottom	72.6 75.0 74.9	74.2	2.14 1.11 1.03
25	Top Middle Bottom	25.3 25.2 23.9	24.8	1.80 1.67 3.47
10	Top Middle Bottom	10.1 10.1 10.1	10.1	0.11 0.13 0.24
2.5	Top Middle Bottom	2.47 2.61 2.42	2.50	1.32 4.43 3.12

Analysis of DNB in the Feed Mixtures

Target Concentration (mg/kg diet)	Date Prepared	Date Analyzed	Concentration by Analysis (mg/kg diet)	% Error
		Week 1		
150	20 Jun 94	21 Jun 94	151	0.53
75	20 Jun 94	21 Jun 94	75.0	0.06
25	10 Jun 94	17 Jun 94	23.8	4.74
10	13 Jun 94	17 Jun 94	10.1	0.92
2.5	13 Jun 94	16 Jun 94	2.58	3.22
		Week 2		
150	22 Jun 94	23 Jun 94	152	1.09
75	22 Jun 94	29 Jun 94	74.2	1.12
25	23 Jun 94	29 Jun 94	24.8	0.78
10	23 Jun 94	29 Jun 94	10.1	1.04
2.5	23 Jun 94	27 Jun 94	2.50	0.09

APPENDIX I

PROTOCOL AND AMENDMENTS

PROTOCOL

14 Day Range Finding and Toxicity Evaluation of 1,3-Dinitrobenzene (DNB) in Fischer (F344) Rats

This study will be conducted in agreement with Good Laboratory Practice Standards, Environmental Protection Agency, Toxic Substances Control Act (TSCA) 40 CFR Part 792 (Federal Register, Vol 54, No. 158, August 17, 1989, pp. 34034 - 34050). All aspects of the studies will be conducted in accordance with written Standard Operating Procedures (SOP) of the performing unit and all raw data and performance documents will be maintained in agreement with GLP. An administratively separate quality assurance unit (QAU from PAI) will monitor the studies to assure adherence to good laboratory practices and the approved SOPs. Any deviation from the protocol or GLP will be noted in the raw data and reflected in the final report.

Testing Facility
A.W. Breidenbach Environmental Research Center
U.S. Environmental Protection Agency
Cincinnati, OH 45268

Prime Contractor (Sponsor)
U.S. Army Biomedical Research and
Development Laboratory, Fort Detrick
Frederick, Maryland 21701-5010

T.v. Ruty 6
Principal Investigator D

G. Reddy, Ph.D., Sponsor Date

T.V. Reddy, Ph.D.

Project Manager

G.R. Olson, DVM, Ph.D. Pathology Associates, Inc.

Quality Assurance W.R. Fox. MA

Pathology Associates, Inc.

6-3.94

Date

14 DAY RANGE FINDING AND TOXICITY EVALUATION OF 1,3-DINITROBENZENE (DNB) IN FISCHER (344)RATS.

RESEARCH PROTOCOL

TIRUMURU V.REDDY,PH.D. PRINCIPAL INVESTIGAROR

F.BERNARD DANIEL,PH.D. CO-PRINCIPAL INVESTIGATOR.

Ecological Monitoring Research Division, Environmental Monitoring Systems Laboratory U.S.Environmental Protection Agency Cincinnati,Ohio 45268

May 26,1994

TITLE: 14 Day Range Finding and Toxicity Evaluation of 1,3-Dinitrobenzene(DNB) in Fischer (344)rats.

BACKGROUND:

Nitroaromatics, such as 1,3-dinitrobenzene (DNB), 1,3,5-trinitrobenzene (TNB), and N-methyl-N,2,4,6-tetranitroaniline (tetryl), have been detected as environmental contaminants of groundwater and soil near production sites and in some instances at military test grounds. The wastewaters discharged from trinitrotoluene (TNT) manufacturing processes contain a variety of aromatic compounds, including DNB and TNB. TNB is formed during the nitration step of TNT synthesis as a result of oxidation of methyl groups. Although the complete mechanism of TNB formation during TNT photolysis is unknown, Burlinson (1980) suggested that it is produced by decarboxylation of 2,4,6-trinitrobenzaldehyde, a major TNT photoproduct. It is also found in aquatic systems and surface soils as a by-products of photolysis of TNT. DNB and TNB are not easily biodegradable, persist in the environment, eventually leach out, and contaminate groundwater near waste disposal sites. Tetryl is an explosive that has been in use, largely for military purposes, since 1906. Wastewaters and soil at the original production sites and other plants devoted to munitions assembly, contain large quantities of tetryl. A recent estimate of tetryl in wastewaters generated from the production of tetryl at Joliet Army Ammunition Plant was about 36 lb/per day of each production line.

Toxicity data on these compounds are limited. The oral LD50 of DNB, TNB and tetryl were 59 mg/kg, 284 mg/kg and greater than 5 g/kg, respectively, in rats for combined sexes. TNB and tetryl were not toxic at 2 g/kg when applied to rabbit skin for 24 hours. However, the dermal LD50 of DNB was 1.99 g/kg for combined sexes of rabbits. None of these compounds produced skin irritation potentials but positive (DNB) and severe (TNB, tetryl) eye irritation potentials in rabbits. The sensitization tests showed that DNB and tetryl are not skin sensitizers while TNB caused mild allergic reaction in guinea pigs. Some of the toxicological and behavioral effects of DNB are: formation of methemoglobin, testicular degeneration and reproductive failure, and weight loss and anemia in hamsters, rats and mice. Neurological and hematological disorders have also been reported in dogs. DNB is rather toxic to humans; the estimated lethal dose range is 5-50 mg/kg. It is readily absorbed through the skin. Fetal doses (amount and route of administration are not given) of tetryl produced toxic degeneration (necrosis) in the kidneys of dogs and rabbits and liver necrosis in dogs (not in rabbits). Tetryl was observed to be a powerful skin sensitizer in ammunition plant workers. Hardy and Maloof (1950) reported effects from accidental exposure of 11 people to tetryl: 2 died, 1 was disabled and 8 did not detect permanent disability. They also reported irreversible liver damage, dermatitis, and upper respiratory irritation following tetryl exposure. The effects of tetryl exposure include gastrointestinal symptoms and epidermal, respiratory, nervous system, hematopoietic and circulatory injury. Atmospheric concentration of 1.5 mg/m3 or below did not produce systemic poisoning in persons working with tetryl. DNB, TNB, and tetryl have been shown to be genotoxic in <u>Salmonella</u> mutagenesis assay. TNB has been shown to form adducts with blood proteins and tissue DNA in rats.

PROTOCOL

1. Study.	14 day range finding and toxicity evaluation of 1,3-
	dinitrobenzene (DNB) in F344 male and female rats.

This study will be started on June 10,94.

2. <u>Purpose</u>. To evaluate subaccute toxicity of DNB when administered in the diet for 14 days and to select an

ideal doses for 90 days subchronic toxicity study.

3. Study Location. A.W. Breidenbach Environmental Research Center

U.S. Environmental Protection Agency

Cincinnati, OH 45268

4. Sponsor and Address. U.S. Army Biomedical Research and Development

Laboratory, Fort Detrick

Frederick, Maryland 21701-5010

5. Principal Investigator. T.V. Reddy, Ph.D., Research Chemist

Environmental Monitoring Systems Laboratory

U.S. Environmental Protection Agency

Cincinnati, Ohio 45268

6. Co-Principal Investigator. F.Bernard Daniel, Ph.D. Director, Ecological

Monnitoring research division, Environmental Monitoring Systems Laboratory, U.S. Environmental

Protection Agency, Cincinnati, Ohio. 45268.

7. Study Coordinator. Barry Wiechman, MS. Pathology associates(PAI),

West Chester, Ohio 45069.

8. Project Manager. G.R. Olson, DVM, Ph.D., Pathology

Associates(PAI), West Chester, Ohio 45069.

9. Regulatory Compliance. This study is conducted according to U.S. EPA

Health Effects testing guidelines (40 CFR 798) in

compliance with GLP (40 CFR 792).

10. Quality Assurance.

The protocol in-life phase, histopathology and final report will be audited by the Quality Assurance Office in accordance with SOP's at Pathology Associates, West Chester, Ohio 45069.

11. Test Material.

1,3-Dinitrobenzene (DNB) Powder (CAS #99-65-0),99% pure, was obtained from Fluka Chemcal Corp., 980 South Second Street, Ronkonkoma, NY. The purity was further confirmed by HPLC.

12. Experimental Design.

A. Selection of Dose: Toxikon Corporation, Woburn, MA 01801 has conducted acute toxicity studies on DNB. They administered DNB in corn oil to rats at a single oral (Bolus) dose and observed the clinical signs for 14 days, following dosing. Based on the results they have established 59 mg/kg BW, as the LD50 dose for male and female rats. Based on the above report, we calculated the following 5 target dose levels to test in Fischer rats, for the 14 day range finding study. (15, 7.5, 2.5, 1, 0.25mg/kg BW). Control rats will be fed only certified 5000-2 powdered chow diet.

B. Preparation of the Diet: Certified powdered Purina laboratory chow(5000-2) will be purchased from Purina labs and stored at 4°C until use. DNB diets are prepared once a week. Just before the diet preparation DNB is removed from the explosion proof storage shelves (kept in designated carcinogen room) weighed in the carcinogen room and mixed with the powdered diet (150 mg/kg). First 150 mg DNB will be mixed with 250g powdered diet and mixed for 15 min. Then an additional 250 g powdered diet is added and mixed for an additional 15 min. Then the remaining diet will be added to bring the DNB concentration as 150 mg/kg; and then mixed for an additional 1 hr. in a mechanical stirrer (Hobart Model C-100 Columbus, OH) for uniform distribution of TNB in the diet. This is also verified by determining the DNB concentration in the diet, taken from three different depths (top,middle and bottom layer) of the mixing chamber soon after diet preparation. Quantitative analysis of DNB is done by HPLC.

The premixed diet (150 mg/kg) is further diluted to 2, 6, 15 and 60 times with fresh powdered diet to obtain the desired DNB concentrations in the diet as 75, 37.5, 25, 10 and 2.5 mg DNB/kg diet, and the expected target doses respectively are 7.50, 2.5, 1.0, and 0.25 mg/kg BW. Individual diet concentrations are determined as described before. The diet feeders are refilled twice and changed once weekly. DNB concentrations are manipulated in such a way that each rat (caged individually) will receive the desired amount of DNB. This is determined by calculating the daily average intake, followed by an adjustment of DNB content in the diet. Dietary intake and water consumption are measured twice a week. Body weights are recorded once a week. There are no known contaminants in the food or water that would interfer

with the purpose or the conduct of the study.

C. Animals: Forty male and female Fischer 344 rats (6 week of age or 120-125 g) will be obtained from Charles River Breeding Laboratory (Portage, MI) and are held for 1W for quarantine (by which time all the serological tests are evaluated). After quarantine 5 rats from each sex are sacrificed and used for necropsy quality controls or base line controls to ensure the animals are healthy and with in the normal limits for all measurements at the time of arrival and after quarantine. Male and female rats are housed individually in polycarbonate shoe boxes with aspen bedding(San I chips supplied by P.J. Murphy, Forest Products Corporation, NJ), and are identified by electronic implants(Bio Medic Data systems Inc., Maywood, NJ.). Food and watere is provided ad libitum. Water is provided in 16 ounce bottles and stoppers and sipper tubes. At all times the animal rooms are maintained on a 12 hour light/dark cycle at 22-23°C with a relative humidity range of 40-60%. All cages are sequentially numbered for identification(5 rats/sex/dose group). Groups of rats are fed 150 mg DNB/kg diet(Gp 1), followed by 75 mg/kg (Gp 2), 25 mg/kg (Gp 3), 10mg/kg(Gp 4), and 2.5 mg DNB/kg diet (Gp 5) daily for 14 days. Group 6 will be given only powered purina chow diet(control). Food and water consumption are recorded 2 times a week. Food spills are taken into account while recording food consumption. Body weights are recorded once a week.

D. Randomization: Using computer-generated random numbers with assignment to groups. At the time of randomization, the weight variation of the animals of each sex used should not exceed \pm 2 SD of the mean weight, and the mean body weights for each group of each sex will not be statistically different.

E. Justification: Rats historically have been used in safety evaluation studies and are recommended by appropriate regulatory agencies.

F. Group designation and dose levels for 14 day toxicity study.

Group	No. of Animals		Dose Levels mgDNB/kg diet	
	Male/Fema	le		
1	5	5	150	
2	5	5	75	
3	5	5	25	
4	5	5	10	
5	5	5	2.5	
6	5	5	0	

G. Analysis of the Diet: The stability of DNB in the diet was determined by keeping the DNB diet at 4°C for one or two weeks and was established that the DNB diet is stable atleast for two weeks. The DNB diets are prepared once a week. The homogeneity of DNB in the freshly prepared diet is determined weekly once, by analyzing the DNB content in the diet by HPLC.

H. Observation of Animals:

(1) Clinical

Observations: Twice daily - mortality and morbidity check.

Once daily - cageside observation for obvious indications of a toxic effect; these effects will be recorded as they are observed.

Data for mortality and morbidity checks and cageside observations will be recorded on the same form. Because these are cageside animal checks, the observations will not be as specific as and may not necessarily duplicate those observations recorded on body weight days when thorough physical examinations are conducted.

(2) Physical

Examinations: At each weighing interval. These observations will include, but not be limited to, changes in: skin and fur; eyes and

but not be limited to, changes in: skin and fur; eyes and mucous membranes; respiratory, circulatory, autonomic and central nervous systems; some motor activity and

behavior.

(3) Body Weight: Prior to treatment, and weekly thereafter.

(4) Food Consumption: Weekly - twice.

(5) Water Consumption: Weekly - twice.

I. Clinical Pathology:

(1) Frequency: At termination.

(2) Number of Animals: All animals (samples per SOP following phenobarbital anesthetic.

J. Tests:

(1) Hematology:

leukocyte count
erythrocyte count
heinz bodies
hemoglobin
methemoglobin
hematocrit
platelet count
differential leukocyte count

(2) Blood Chemistry:

glucose
cholesterol
sodium
potassium
total protein
albumin
calcium
total bilirubin
urea nitrogen
creatinine
aspartate aminotransferase
alanine aminotransferase
alkaline phosphatase

K. Termination:

(1) unscheduled Sacrifices and Deaths:

Necropsies, by trained personnel using procedures approved by board-certified pathologists, will be conducted on all moribund animals and on all animals that die.

(2) Sacrifice:

After 14 days of treatment, all surviving animals will be weighed, and then fasted for 12 hrs. The following morning all rats will be

anesthetized with sodium pentobarbital, and exsanguinated. Necropsies will be conducted on each animal by trained personnel using procedures approved by board-certified pathologists.

A pathologist will be readily available for consultation (further participation by a pathologist is available).

L. Postmortem Procedures:

(1) Gross Necropsy

The necropsy will include examination of:

External surface

All orifices

Cranial cavity

Carcass

External surface of the brain (at necropsy); Thoracic, abdominal and pelvic cavities and their viscera.

(2) Organ Weights

For each terminally sacrificed animal, the following organs (when present) will be weighed following careful dissection and trimming to remove fat and other contiguous tissue in a uniform manner:

brain

lungs

liver

thymus testes with epididymides/ovaries

spleen kidneys

heart

adrenals

(3) Tissue Preservation

The following tissues (when present) from each animal will be preserved in 10% neutral buffered formalin:

skin

ileum

mandibular and mesenteric lymph nodes colon cecum

mesenteric lymph mammary glands thigh muscle

rectum liver

sciatic nerve

pancreas

sternum with marrow femur with marrow

larynx thymus trachea

lungs and bronchi

heart and aorta thyroid

parathyroids esophagus stomach duodenum jejunum

tongue salivary gland spleen kidneys adrenals

urinary bladder seminal vesicles

prostate

testes, including epididymis

ovaries uterus

nasal cavity and nasal turbinates

brain pituitary

preputial or clitoral glands

Zymbal's gland thoracic spinal cord

M. Histopathology:

(1) Following necropsy, a list of all gross lesions recorded will be submitted to the project officer at U.S. Army Biomedical Research and Development Laboratory for his evaluation and for any additional histopathology than those described below.

Histopathological evaluations are to be done on the following tissues from all the animals. Male an female from highest dose group and (150 mgDNB/kg/diet groups) and untreated controls. The tissues examined under light microscope are as follows:

cerebrum
cerebellum
trachea
thyroid
parathyroid
esophagus
salivary gland
harderian gland

heart
aorta
lung
thymus
spleen
mesenteric lymph node

pancreas
cecum
colon
rectum
stomach
skeletal muscle
sciatic nerve
tongue

skin
mammary gland
nasal region
sternum
femur
vertebrae
spinal cord

liver kidney urinary bladder duodenum adrenals pituitary eye(s) jejunum

auditory sebaceous gland

ileum

MALE

FEMALE

accessory sex glands epididymis testes uterus ovaries

An average of 12 slides will be prepared for each rat covering all the tissues shown above (3 or 4 tissues are fixed on each slide). APPApproximately 240 slides from 20 rats(5 male and 5 female from 150 mg DNB\kg dose group and 5 rats each from control group). Based on the results from dose group tissues from other dose groups will be examined as needed. Following completion of each study all wet tissues, paraffin blocks and slides and all raw data will be stored in EPA archives.

- N. Final Report: Four months after the termination of the in-life phase of the study, a final report which includes the following information (as appropriate) will be prepared and submitted to the Sponsor:
 - (1) Experimental Design and Methods
 - (2) Results
 mortality
 clinical observations
 body weights

organ weights and organ/body

weight ratios gross pathology histopathology

food and liquid consumption clinical pathology tests

- O. Statistical Evaluation: Stat view computer software will be used for statistical analysis in 14-day and 90-day study for statistical analysis. Analysis will be done by Dr. Jonie Torsella, Okridge institue of science and education. Dunnet's t-test will be used for comparing treatment group.

 Kruskal-Wallis rank sums will be used to examine the differences among the treatment groups and Wilcoxon rank sum test was used to analyze pairwise differences between the control and each dose group.
- P. Schedule: The study start and completion dates will be added by amendment.

Amendment 1 for United States Army Study 94-003 14-DAY TOXICITY EVALUATION OF 1,3-DINITROBENZENE IN FISCHER (F344) RATS

For
United States Army
Biomedical Research and Development Laboratory
Fort Detrick
Frederick, MD 21701-5010

The purpose of Amendment 1 is to correct a typographical error in the protocol.

1. Page 4 of the protocol:

B. Line 10: Change TNB to DNB.

Reason: Typographical error.

Amendment 1 Approval

U.S. Army Medical Research and Development Laboratory Fort Detrick Frederick, Maryland 21701-5010 AW Breidenbach Environmental Research Center U.S. Environmental Protection Agency Cincinnati, Ohio 45268

G. Beddy Ph.D. Sponsor Date

T.V. Reddy, Ph.D., Pi

Date

Willa Fox, MA, QA

Date

Deviations from GLP's and Protocol

- 1. Preparation of the test diet stock was changed in order to obtain a more uniform mixture.
- 2. Sampling for homogeneity was changed due to the depth of the diet in the container. Samples were taken from different areas of the container and not top, middle and bottom as stated in the analysis section.

Timm v Redox Tirumuru V. Reddy, Ph.D.

DISTRIBUTION LIST

Commander

ATTN: SGRD-UBZ-C

U.S. Army Biomedical Research and Development Laboratory

Fort Detrick, Frederick, MD 21702-5010

Commander

ATTN: MCMR-RMI-S

U.S. Army Medical Research and Materiel Command

Fort Detrick, Frederick, MD 21702-5012

Commander/Director

U.S. Army Corps of Engineers

Construction Engineering Research Laboratory

Environmental Division

P.O. Box 4005

Champaign, IL 61820

Commandant

Academy of Health Sciences, U.S. Army

ATTN: DRXTH-ES

Aberdeen Proving Ground, MD 21010-5000

Commander

U.S. Army Environmental Hygiene Agency

ATTN: Library

Aberdeen Proving Ground, MD 21020-5000

Commander

U.S. Army Environmental Center

ATTN: S-FIM-AEC-TSS (Mr. R. L. Muhly)

Aberdeen Proving Ground, MD 21010-5401